

09674379 .012502

414 Rec'd PCT/PTO 30 OCT 2000

09/674379

LAW OFFICES

SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC

2100 PENNSYLVANIA AVENUE, N.W.

WASHINGTON, DC 20037-3213

TELEPHONE (202) 293-7060

FACSIMILE (202) 293-7860

www.sughrue.com

October 30, 2000

BOX PCTAssistant Commissioner for Patents
Washington, D.C. 20231PCT/PCT/JP99/02284
-filed April 28, 1999

Re: Application of Tasuku HONJO, Kei TASHIRO and Tomoyuki NAKAMURA
A NOVEL POLYPEPTIDE, A cDNA ENCODING THE POLYPEPTIDE AND
UTILIZATION THEREOF
Our Ref: Q61531

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☒ an English translation of the International Application.
- ☒ two (2) sheet(s) of informal drawings.
- ☒ Notification Concerning Submission or Transmittal of Priority Document w/faithful translation
- ☒ thirty-eight (38) pages of Sequence Listing and a 3.5" disk containing Sequence Listing.
- ☒ Statement in Support of Submission in Accordance with 37 C.F.R. § 1.821.
- ☒ International Preliminary Examination Report
- ☒ International Search Report, Information Disclosure Statement and Form PTO-1449.
- ☒ Preliminary Amendment

The Declaration and Power of Attorney and Assignment, will be submitted at a later date.

It is assumed that copies of the International Application, the International Search Report, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned can easily provide them upon request.

The Government filing fee is calculated as follows:

Total claims	19	-	20	=		x	\$18.00	=	\$0.00
Independent claims	1	-	3	=		x	\$80.00	=	\$0.00
Base Fee									\$860.00
Multiple Dependent Claim Fee									\$270.00

TOTAL FEE\$1130.00

A check for the statutory filing fee of \$1130.00 is attached. You are also directed and authorized to charge or credit any difference or overpayment to said Account. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Priority is claimed from April 28, 1998 based on Japanese Application No. Hei. 10-119731.

Since October 28, 2000 (30 months from the priority date) fell on a Saturday, the submission of these papers on Monday, October 30, 2000, is sufficient for entry of National Stage of the above application.

Respectfully submitted,

for Mark Boland

Registration No. 32,197

Reg No 32,765

MXB/amt

CALIFORNIA OFFICE • 1010 EL CAMINO REAL • MENLO PARK, CA 94025 • TELEPHONE (650) 325-5800 • FACSIMILE (650) 325-6606

FICE • TOEI NISHI SHIMBASHI BLDG. 4F • 13-5 NISHI SHIMBASHI 1-CHOME • MINATO-KU, TOKYO 105-0003, JAPAN • TELEPHONE (03) 3503-3760 • FACSIMILE (03) 3503-3756

Rec'd PCT/PTO 10 DEC 2001

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/B

In re application of

Tasuku HONJO, et al.

Appln. No.: 09/674,379

Group Art Unit: Not Yet Assigned

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: October 30, 2000

For: A NOVEL POLYPEPTIDE, A CDNA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please add the following new claims:

14. (new) A method for promoting smooth muscle growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 9.

15. (new) A pharmaceutical composition for promoting smooth muscle cell growth or vasculogenesis which comprises administering to a mammalian subject a therapeutically effective amount of an antibody of claim 9.

REMARKS

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,



Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860
MXB/amt
Date: December 10, 2001

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 14 and 15 are added as new claims.

09674379 012502

09/674379

534 Rec'd PCT/PTC 30 OCT 2000
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3/a

In re application of

Tasuku HONJO, et al.

Appln. No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: October 30, 2000

Examiner: Not Yet Assigned

For: A NOVEL POLYPEPTIDE, A cDNA ENCODING THE POLYPEPTIDE AND
UTILIZATION THEREOF

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Page 4, line 25, please delete "1, 4, 6, 9, 11 or 14," and insert --3, 4, 8, 9, 13 or 14,--

Page 4, line 27, please delete "2, 5, 7, 10," and insert --1, 5, 6, 10,--

Page 4, line 28, please delete "12 or 15," and insert --11 or 15,--

Page 5, line 2, please delete "3, 8 or 13" and insert --2, 7 or 12--

Page 5, line 10, please delete "1, 4, 6, 9, 11 or 14" and insert --3, 4, 8, 9, 13 or 14--

Page 5, line 15, please delete "2, 5, 7, 10, 12 or" and insert --1, 5, 6, 10, 11 or--

Page 5, line 17, please delete "2, 5, 7, 10," and insert --1, 5, 7, 10,--

Page 5, line 18, please delete "12 or 15" and insert --11 or 15--

Page 5, line 21, after "SEQ ID NO." please delete "1" and insert --3--

Page 5, line 22, please delete "4, 6, 9, 11 or 14" and insert --4, 8, 9, 13 or 14--

Page 5, line 24, please delete "1, 4," and insert --3, 4,--

Page 5, line 25, please delete "6, 9, 11 or 14" and insert --8, 9, 13 or 14--

Page 6, line 1, please delete "1, 4, 6, 9, 11 or 14" and insert --3, 4, 8, 9, 13 or 14--

PRELIMINARY AMENDMENT

Q61531

Page 6, line 3, after "SEQ ID NO." please delete "1" and insert --3--
 Page 6, line 7, please delete "1, 4, 6, 9, 11 or 14" and insert --3, 4, 8, 9, 13 or 14--
 Page 6, line 12, please delete "2, 5, 7, 10, 12 or 15" and insert --1, 5, 6, 10, 11 or 15--
 Page 6, line 14, please delete "2, 5, 7, 10, 12 or 15" and insert --1, 5, 6, 10, 11 or 15--
 Page 6, line 19, please delete "2, 5, 7, 10, 12 or 15" and insert --1, 5, 6, 10, 11 or 15--
 Page 7, line 4, after "SEQ ID NO." please delete "2" and insert --1--
 Page 7, line 5, please delete "3, 5, 7, 8, 10, 12, 13 or 15" and insert --2, 5, 6, 8, 10, 11, 12
 or 15--
 Page 8, line 4, after "SEQ ID NO." please delete "1" and insert --3--
 Page 8, line 8, please delete "1, 4, 6, 9, 11 or" and insert --3, 4, 8, 9, 13 or--
 Page 8, line 17, please delete "1, 4, 6, 9, 11 or 14" and insert --3, 4, 8, 9, 13 or 14--
 Page 8, line 23, please delete "3, 8 or 13" and insert --2, 7 or 12--
 Page 11, line 19, please delete "2, 5, 7, 10, 12 or" and insert --1, 5, 6, 10, 11 or--
 Page 12, line 9, please delete "2, 7 or 12" and insert --1, 6 or 11--
 Page 12, line 10, please delete "3, 8 or 13" and insert --2, 7 or 12--
 Page 12, line 13, please delete "2, 5, 7, 10, 12" and insert --1, 5, 6, 10, 11--
 Page 13, line 14, please delete "2, 5, 7, 10, 12 or 15" and insert --1, 5, 6, 10, 11 or 15--
 Page 33, line 23, after "SEQ ID NO." please delete "3" and insert --2--
 Page 33, line 25, after "SEQ ID NO." please delete "2" and insert --1--
 Page 33, line 26, after "SEQ ID NO." please delete "1" and insert --3--
 Page 33, line 27, after "SEQ ID NO." please delete "3" and insert --2--
 Page 35, line 9, after "SEQ ID NO." please delete "3" and insert --2--
 Page 35, line 11, after "NO." please delete "7 and 8" and insert --6 and 7--
 Page 35, line 14, after "SEQ ID NO." please delete "8" and insert --7--
 Page 35, line 16, after "in SEQ ID NO." please delete "6" and insert --8--
 Page 35, line 16, after "of SEQ ID NO." please delete "1" and insert --3--
 Page 35, line 17, after "SEQ ID NO." please delete "6" and insert --8--
 Page 35, line 19, after "SEQ ID NO." please delete "8" and insert --7--
 Page 36, line 5, before "was determined" please delete "13" and insert --12--
 Page 36, line 7, after "NO." please delete "12" and insert --11--
 Page 36, line 7, after "in SEQ ID NO." please delete "11" and insert --13--

PRELIMINARY AMENDMENT

Q61531

Page 36, line 14, after "SEQ ID NO." please delete "13" and insert --12--

Page 36, line 24, after "SEQ ID NO." please delete "3" and insert --2--

Page 38, line 17, after "SEQ ID NO." please delete "13" and insert --12--

Page 39, line 11, after "SEQ ID NO." please delete "13" and insert --12--

Page 40, line 14, after "SEQ ID NO." please delete "1" and insert --3--

Page 40, line 15, after "SEQ ID NO." please delete "1" and insert --3--

Page 40, line 16, after "SEQ ID NO." please delete "1" and insert --3--

IN THE CLAIMS:

Claim 1, line 2, after "SEQ ID NO." please delete "11" and insert --13--

Claim 2, line 2, after "SEQ ID NO." please delete "11" and insert --13--

Claim 4, line 2, after "SEQ ID NO." please delete "12" and insert --11--

Claim 5, line 2, after "SEQ ID NO." please delete "13" and insert --12--

REMARKS

The amendments to the specification and claims are necessitated by the revision of the Sequence Listing.

The Sequence Listing was originally prepared using PatentIn version 2.0. Due to the requirement that Sequence Listings now be prepared using PatentIn version 2.1 or 3.0, a new Sequence Listing was prepared. The order of the sequences prepared using the new Sequence Listing was altered, as compared to the Sequence Listing prepared using PatentIn version 2.0. Therefore, the specification and claims have been amended to match the updated Sequence Listing. Accordingly, no new matter has been introduced.

PRELIMINARY AMENDMENT

Q61531

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,



Mark A. Hissong
Registration No. 44,765

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: October 30, 2000

Specification

A novel polypeptide, a cDNA encoding the polypeptide and utilization thereof

Field of the Invention

The present invention provides a novel polypeptide, a cDNA encoding the polypeptide, and utilization thereof.

Background of the Invention

In modern medical research, cardiovascular biology is a field that attracts considerable attention because cardiovascular disease is the leading cause of mortality. Cardiovascular research has revealed important facts about neointimal formation and arterial remodeling, both of which are thought to contribute to plaque formation in atherosclerosis and blood vessel narrowing. For example, there are three aspects of the cellular process in hypercholesterolaemia induced blood vessel damage in animal models that mimic human development of arteriosclerotic coronary disease. The three elements that form lesions on the artery wall are: a) proliferation of smooth muscle cells, macrophages and lymphocytes, b) formation of connective tissues (mainly elastic fiber proteins, collagen and proteoglycans made by smooth muscle cells in a process similar to scar formation), and c) the accumulation of lipid and cholesterol in the newly formed connective tissue matrices. The exact sequence of the three damaging elements are debatable, but it is clear that the abnormal dedifferentiation, redifferentiation and growth of smooth muscle cells contribute structurally to vessel damage. Moreover, another significant pathological process that involves abnormal smooth muscle cell growth is restenosis after Percutaneous transluminal coronary angioplasty (PTCA).

The present inventors made reasonable efforts, by isolation of the

molecules related to participation of smooth muscle cells in angiogenesis, for the aim to utilize them for regulation of abnormal proliferation of smooth muscle cells such like described above.

In order to obtain a certain polypeptide or cDNA coding for the same, there has been generally employed a method composed of detecting the aimed biological activity in a tissue or a cell culture medium, then identifying a polypeptide as substance of the activity through the isolation and purification and isolating a gene encoding the polypeptide or expression-cloning method to isolate a gene by access of the biological activity of the polypeptide encoded by it.

Because in many cases, however, physiologically active polypeptides have various biological activities, when taking the method to approaches based on a certain activity to isolate a gene, it has increasingly been happened that the gene is turned out to be identical to a known gene which has another activity after spending much efforts to isolate it. And because, in many cases, biological factors are produced only in a very slight amount or only in a specific condition, it is often made difficult to isolate and purify a factor and detect its biological activity.

Recent rapid developments in techniques for constructing cDNAs and sequencing techniques have made it possible to quickly sequence a large amount of cDNAs. By utilizing these techniques, a process, which comprises constructing cDNAs at random, identifying the nucleotide sequences thereof, expressing novel polypeptides encoded by them, is now in progress. Although this process is advantageous in that a gene can be cloned and information regarding its nucleotide sequence can be obtained without any biochemical or genetic analysis, the target gene can be discovered thereby only accidentally in many cases.

Disclosure of the Invention

The present inventors investigated to find novel factors (polypeptides) which are useful for study or for the treatment or diagnosis of diseases induced by abnormal proliferation of smooth muscle. Especially, we had aimed secreted proteins and membrane proteins which have signal sequences for secretion.

The present inventors have studied cloning method of genes coding proliferation and/or differentiation factors functioning in hematopoietic systems and immune systems. Focusing their attention on the fact that most of the secretory proteins such as proliferation and/or differentiation factors (for example various cytokines) and membrane proteins such as receptors thereof (hereafter these proteins will be referred to generally as secretory proteins and the like) have sequences called signal peptides in the N-termini, the inventors conducted extensive studies on a process for efficiently and selectively cloning a gene coding for a signal peptide. Finally, we have successfully invented a screening method for cDNAs having sequence encoding signal peptides, we called the method as signal sequence trap (SST) (Japanese Patent Publication No. 6-315380).

We also developed yeast SST method on the same concept. By the method using yeast, genes including sequence encoding signal peptide can be identified more easily and effectively (USP No. 5,536,637).

By using the present method, the present inventors identified novel secreted protein produced by mouse embryonic heart and human kidney and a cDNA fragments encoding them, and by using the sequence information of the cDNA fragments they isolated each full-length cDNA from mouse embryonic heart and human kidney. And they discovered that the polypeptides had functions to suppress smooth muscle cells.

The present cDNA sequence was named as a clone mouse A55 and isolated

from cDNA library derived from mouse embryonic heart based on genetic information obtained by using the Yeast SST method described above. The clone, mouse A55 is a full-length cDNA encoding a secreted polypeptide (which is called mouse A55 polypeptide here).

The present cDNA sequence was named as a clone human A55 and isolated from cDNA library derived from human brain based on genetic information obtained from human kidney by using the Yeast SST method described above. The clone, human A55 is a full-length cDNA encoding a secreted polypeptide (which is called human A55 polypeptide here).

There was no DNA sequence which is identical to that of mouse and human A55 of the present invention, when DNA sequence of mouse and human A55 were compared with data base by BLASTN and FASTA. And there was no polypeptides which is identical to that of mouse and human A55 of the present invention, when amino acid sequence of mouse and human A55 was compared with data base by BLASTX, BLASTP and FASTA. So the polypeptides of the present invention are considered to be novel.

The inventors discovered that the polypeptides had functions to suppress smooth muscle cells. Accordingly, the polypeptides may be useful for treatment of diseases related to abnormal proliferation of smooth muscle cells, for example, arteriosclerotic coronary disease, neointimal formation which results in restenosis after percutaneous transluminal coronary angioplasty and myosarcoma.

The present invention provides:

- 1) a polypeptide comprising an amino acid sequence shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14,
- 2) a cDNA encoding the polypeptide described above (1),
- 3) a cDNA having an nucleotide sequence shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15,

- 4) a cDNA that consists of an nucleotide sequence shown in SEQ ID NO. 3, 8 or 13.

Brief Description of Figures

- Fig. 1 It shows that mouse A55 protein inhibits proliferation of rat aortic vascular smooth muscle cells which was stimulated by PDGF.
- Fig. 2 It shows that human A55 protein inhibits proliferation of rat aortic vascular smooth muscle cells which was stimulated by PDGF.

Detailed Discliption

The present invention is concerned with a polypeptide that comprising the amino acid sequence shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14 in substantially purified form, a homologue thereof, a fragment of the sequence and a homologue of the fragment.

Further, the present invention is concerned with a cDNA encoding the above peptides. More particularly the present invention is provided cDNA comprising the nucleotide sequence shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15, and cDNA containing a fragment which is selectively hybridizing to the cDNA that comprising nucleotide sequence shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15. Complementary sequence of the above nucleotide sequence is also included in cDNA selectively hybridized. Hybridization are performed in an stringent condition.

A polypeptide comprising amino acid sequence shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14 in substantially purified form will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is that of the SEQ ID NO. 1, 4, 6, 9, 11 or 14.

A homologue of polypeptide comprising amino acid sequence shown in

SEQ ID NO. 1, 4, 6, 9, 11 or 14 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the polypeptide of SEQ ID NO. 1 over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 more contiguous amino acids. Such a polypeptide homologue will be referred to a polypeptide of the present invention.

Generally, a fragment of polypeptide comprising amino acid sequence shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14 or its homologues will be at least 10, preferably at least 15, for example 20, 25, 30, 40, 50 or 60 amino acids in length, and are also referred to by the term "a polypeptide of the present invention".

A cDNA capable of selectively hybridizing to the cDNA comprising nucleotide sequence shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15 will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% homologous to the cDNA of SEQ ID NO. 2, 5, 7, 10, 12 or 15 over a region of at least 20, preferably at least 30, for instance 40, 60 or 100 or more contiguous nucleotides. Such cDNA will be referred to "a cDNA of the present invention".

Fragments of the cDNA comprising nucleotide sequence shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15 will be at least 10, preferably at least 15, for example 20, 25, 30 or 40 nucleotides in length, and will be also referred to "a cDNA of the present invention" as used herein.

A further embodiment of the present invention provides replication and expression vectors carrying cDNA of the invention. The vectors may be, for example, plasmid, virus or phage vectors provided with an origin of replication, optionally a promoter for the expression of the said cDNA and optionally a regulator of the promoter. The vector may contain one or more selectable marker genes, for example a ampicillin resistance gene. The vector may be used in vitro, for example of the production of RNA corresponding

to the cDNA, or used to transfect or transfect a host cell.

A further embodiment of the present invention provides host cells transformed with the vectors for the replication and expression of the cDNA of the invention, including the nucleotide sequence shown in SEQ ID NO. 2, 3, 5, 7, 8, 10, 12, 13 or 15 or the open reading frame thereof. The cells will be chosen to be compatible with the vector and may for example be bacterial, yeast, insect or mammalian.

A further embodiment of the present invention provides a method of producing a polypeptide which comprises culturing host cells of the present invention under conditions effective to express a polypeptide of the invention. Preferably, in addition, such a method is carried out under conditions in which the polypeptide of the invention is expressed and then produced from the host cells.

cDNA of the present invention may also be inserted into the vectors described above in an antisense orientation in order to provide for the production of antisense RNA. Such antisense RNA may be used in a method of controlling the levels of a polypeptide of the invention in a cell.

The invention also provides monoclonal or polyclonal antibodies against a polypeptide of the invention. The invention further provides a process for the production of monoclonal or polyclonal antibodies to the polypeptides of the invention. Monoclonal antibodies may be prepared by common hybridoma technology using polypeptides of the invention or fragments thereof, as an immunogen. Polyclonal antibodies may also be prepared by common means which comprise inoculating host animals, for example a rat or a rabbit, with polypeptides of the invention and recovering immune serum.

The present invention also provides pharmaceutical compositions containing a polypeptide of the invention, or an antibody thereof, in association with a pharmaceutically acceptable diluent and/or carrier.

The polypeptide of the present invention includes that which a part of their amino acid sequence is lacking (e.g., a polypeptide comprised of the only essential sequence for revealing a biological activity in an amino acid sequence shown in SEQ ID NO.1), that which a part of their amino acid sequence is replaced by other amino acids (e.g., those replaced by an amino acid having a similar property) and that which other amino acids are added or inserted into a part of their amino acid sequence, as well as those comprising the amino acid sequence shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14.

As known well, there are one to six kinds of codon as that encoding one amino acid (for example, one kind of codon for Methioine (Met), and six kinds of codon for leucine (Leu) are known). Accordingly, the nucleotide sequence of cDNA can be changed in order to encode the polypeptide having the same amino acid sequence.

The DNA of the present invention, specified in (2) includes a group of every nucleotide sequences encoding polypeptides (1) shown in SEQ ID NO. 1, 4, 6, 9, 11 or 14. There is a probability that yield of a polypeptide is improved by changing a nucleotide sequence.

The cDNA specified in (3) is the embodiment of the cDNA shown in (2), and indicate the sequence of natural form.

The cDNA shown in (4) indicates the sequence of the cDNA specified in (3) with natural non-translational region.

cDNA carrying nucleotide sequence shown in SEQ ID NO. 3, 8 or 13 is prepared by the following method:

Brief description of Yeast SST method (see USP No. 5,536,637) is as follows.

Yeast such as *Saccharomyces cerevisiae* should secrete invertase into the medium in order to take sucrose or raffinose as a source of energy or

carbon. (Invertase is an enzyme to cleave raffinose into sucrose and melibiose, sucrose into fructose and glucose.) It is known that many known mammalian signal peptide make yeast secrete its invertase. From these knowledge, SST method was developed as a screening method to find novel signal peptide which make it possible can to secrete yeast invertase from mammalian cDNA library. SST method uses yeast growth on raffinose medium as a marker. Non-secretory type invertase gene SUC2 (GENBANK Accession No. V01311) lacking initiation codon ATG was inserted to yeast expression vector to prepare yeast SST vector pSUC2.

In this expression vector, ADH promoter, ADH terminator (both were derived from AAH5 plasmid (Gammerer, Methods in Enzymol. 101, 192-201, 1983)), 2u ori (as a yeast replication origin), TRP1 (as a yeast selective marker), ColE1 ori (as a E. Coli replication origin) and ampicillin resistance gene (as a drug resistance marker) were inserted. Mammalian cDNA was inserted into the upstream of SUC2 gene to prepare yeast SST cDNA library. Yeast lacking secretory type invertase, was transformed with this library. If inserted mammalian cDNA encodes a signal peptide, yeast could be survive in raffinose medium as a result of restoring secretion of invertase. Only to culture yeast colonies, prepare plasmids and determine the nucleotide sequence of the insert cDNAs, it is possible to identify novel signal peptide rapidly and easily.

Preparation of yeast SST cDNA library is as follows:

- (1) mRNA is isolated from the targeted cells, second-strand synthesis is performed by using random primer with certain restriction enzyme (enzyme I) recognition site,
- (2) double-strand cDNA is ligated to adapter containing certain restriction endonuclease (enzyme II) recognition site, differ from enzyme I, digested with enzyme I and fractionated in a appropriate size,

(3) obtained cDNA fragment is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted and the library was transformed.

Detailed description of each step is as follows:

(1) mRNA is isolated from mammalian organs and cell lines stimulate them with appropriate stimulator if necessary) by known methods (Molecular Cloning (Sambrook, J., Fritsch, E. F. and Maniatis, T., Cold Spring Harbor Laboratory Press, 1989) or Current Protocol in Molecular Biology (F. M. Ausubel et al, John Wiley & Sons, Inc.) if not remark especially).

Mouse embryonic heart is chosen as a tissue source. Double-strand cDNA synthesis using random primer is performed by known methods.

Any sites may be used as restriction endonuclease recognition site I which is linked to adapter and restriction endonuclease recognition site II which is used in step (2), if both sites are different each other. Preferably, XhoI is used as enzyme I and EcoRI as enzyme II.

In step (2), cDNA is created blunt-ends with T4 DNA polymerase, ligated enzyme II adapter and digested with enzyme I. Fragment cDNA is analyzed with agarose-gel electrophoresis and is selected cDNA fraction ranging in size from 300 to 800 bp. As mentioned above, any enzyme may be used as enzyme II if it is not same the enzyme I.

In step (3), cDNA fragment obtained in step (2) is inserted into yeast expression vector on the upstream region of invertase gene which signal peptide is deleted. E. coli transformed with the expression vector. Many vectors are known as yeast expression plasmid vector. For example, YEp24 is also functioned in E. Coli. Preferably pSUC2 as described above is used.

Many host E. Coli strains are known for transformation, preferably DH10B competent cell is used. Any known transformation method is available, preferably it is performed by electroporation method. Transformant is

However not every All of the clones do not contain cDNA fragment. Further all of the gene fragments do not encode unknown signal peptides. It is therefore necessary to screen a gene fragment encoding for an unknown signal peptide from the library.

Therefore, screening of fragments containing a sequence encoding an appropriate signal peptide is performed by transformation of the cDNA library into *Saccharomyces cerevisiae* (e.g. YTA55 strain) which lack invertase (it may be prepared by known methods.). Transformation of yeast is performed by known methods, e.g. lithium acetate method. Transformant is cultured in a selective medium, then transferred to a medium containing raffinose as a carbon source. Survival colonies are selected and then prepared plasmid. Survival colonies on a raffinose-medium indicates that some signal peptide of secretory protein was inserted to this clone.

Isolated positive clones is determined the nucleotide sequence. As to a cDNA encodes unknown protein, full-length clone may be isolated by using cDNA fragment as a probe and then determined to obtain full-length nucleotide sequence. These manipulation is performed by known methods.

Once the nucleotide sequences shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15 are determined partially or preferably fully, it is possible to obtain cDNA encode mammalian protein itself, homologue or subset of the invention.

cdna library or mRNA derived from mammals was screened by PCR with any synthesized oligonucleotide primers or by hybridization with any fragment as a probe. It is possible to obtain cdna encodes other mammalian homologue protein from other mammalian cdna or genome library.

If a cDNA obtained above contains a nucleotide sequence of cDNA fragment obtained by SST (or consensus sequence thereof), it will be thought that the cDNA encodes signal peptide. So it is clear that the cDNA will be

full-length or almost full. (All signal peptides exist at N-termini of a protein and are encoded at 5'-temini of open reading frame of cDNA.)

The confirmation may be carried out by Northern analysis with the said cDNA as a probe. It is thought that the cDNA is almost complete length, if length of the cDNA is almost the same length of the mRNA obtained in the hybridizing band.

The present invention supplies full-length protein and also its mature protein sequence. The full-length protein sequence deduced from nucleotide sequences shown in SEQ ID NO. 2, 7 or 12. Mature proteins are obtained by expressing full-length cDNAs shown in SEQ ID NO. 3, 8 or 13 in mammalian cells or other host cells. Mature protein sequences are deduced from their full-length amino acid sequences.

Once the nucleotide sequences shown in SEQ ID NOs. 2, 5, 7, 10, 12 or 15 are determined, cDNAs of the present invention are obtained by chemical synthesis, or by hybridization making use of nucleotide fragments which are chemically synthesized as a probe. Furthermore, cDNAs of the present invention are obtained in desired amount by transforming a vector that contains the cDNA into a proper host, and culturing the transformant.

The polypeptides of the present invention may be prepared by:

- (1) isolating and purifying from an organism or a cultured cell,
 - (2) chemically synthesizing, or
 - (3) using recombinant DNA technology,
- preferably, by the method described in (3) in industrial production.

Examples of expression system for (host-vectoer system) producing a polypeptide by using recombinant DNA technology are the expression systems of bacteria, yeast, insect cells and mammalian cells.

In the expression of the polypeptide, for example, in E. Coli, the expression vector is prepared by adding the initiation codon (ATG) to 5'

end of a DNA encoding mature peptide, connecting the DNA thus obtained to the downstream of a proper promoter (e.g., trp promoter, lac promoter, λ PL promoter, T7 promoter etc.), and then inserting it into a vector (e.g., pBR322, pUC18, pUC19 etc.) which functions in an E. coli strain.

Then, an E. coli strain (e.g., E. coli DH1 strain, E. coli JM109 strain, E. coli HB101 strain, etc.) which is transformed with the expression vector described above may be cultured in a appropriate medium to obtain the desired polypeptide. When a signal peptide of bacteria (e.g., signal peptide of pel B) is utilized, the desired polypeptide may be also released in periplasm. Furthermore, a fusion protein with other polypeptide may be also produced easily.

In the expression of the polypeptide, for example, in a mammalian cells, for example, the expression vector is prepared by inserting the DNA shown in SEQ ID NO. 2, 5, 7, 10, 12 or 15 into the downstream of a proper promoter (e.g., SV40 promoter, LTR promoter, metallothionein promoter etc.) in a proper vector (e.g., retrovirus vector, papilloma virus vector, vaccinia virus vector, SV40 vector, etc.) a proper mammalian cell (e.g., monkey COS-7 cell, Chinese hamster CHO cell, mouse L cell etc.) is transformed with the expression vector thus obtained, and then the transformant is cultured in a proper medium to get a desired polypeptide in the culture medium. Further, fusion protein may be produced by linking cDNA fragment encoding other polypeptide such as Fc portion of an antibody. The polypeptide thus obtained may be isolated and purified by conventional biochemical methods.

Industrial Utility

The polypeptides of the present invention and cDNA encoding them are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below.

Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of cDNA encoding them (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

We have been confirmed that the said polypeptide possess the suppressing activity on the differentiation of vascular smooth muscle cells. Accordingly, the polypeptides may be useful for treatment of diseases related to abnormal proliferation of smooth muscle cells, for example, arteriosclerotic coronary disease, neointimal formation which results in restenosis after percutaneous transluminal coronary angioplasty and myosarcoma.

But not limit the present invention, the present polypeptide may show the following activity :

<Cytokine activity and cell proliferation/differentiation activity>

The protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.

Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity.

The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines.

<Immune stimulating/suppressing activity>

The protein of the present invention may also exhibit immune

These immune deficiencies may be genetic or be caused by viral (e.g. HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders.

Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma or other respiratory problems.

<Hematopoiesis regulating activity>

forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis.

The said biological activities are concerned with the following all or some example(s). e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility.

for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells;

in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression;

in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions;

and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e. in conjunction with bone marrow transplantation) as normal cells or genetically manipulated for gene therapy.

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

The activity of a protein of the invention may, among other means, be measured by the following methods :

<Tissue generation/regeneration activity>

The protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, Ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair, and in the treatment of burns, incisions and ulcers.

The protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing the protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

The protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. The protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces

tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/Ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments.

The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon Ligament cells or progenitors ex vivo for return in vivo to effect tissue repair.

The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies. as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue.

More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries,

peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome.

Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

It is expected that the protein of the present invention may also exhibit activity for generation of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting or suppressing the proliferation of cells comprising such tissues. Part of the desired effects may be by inhibition of fibrotic scarring to allow normal tissue to regenerate.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
<Activin/Inhibin activity>

The protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH).

Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin *a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient

amounts of other inhibins can induce infertility in these mammals.

Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-*b group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See for example, USP 4,798,885. The polypeptide of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

<Chemotactic/chemokinetic activity>

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, neutrophils, T-cells, mast cells, eosinophils and/or endothelial cells.

Chemotactic and chemokinetic proteins can be used to mobilized or attract a desired cell 'population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

<Hemostatic and thrombolytic activity>

The protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction or stroke).

<Receptor/ligand activity>

The protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses).

Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

<Nutritional uses>

Proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source

and use as a source of carbohydrate. In such cases the protein of the present invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein of the invention can be added to the medium in or on which the microorganism is cultured.

<Cadherin/Tumor invasion suppresser activity>

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (autoimmune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherin.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes.

Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppresser role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and cDNAs of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or cDNAs into cancer cells can reduce or eliminate the cancerous change observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and cDNAs of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and cDNA of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be

detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and cDNAs of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects.

Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

<Tumor Inhibiting activity>

In addition to the activities described above for immunological treatment or prevention of tumors, the protein of the invention may exhibit other anti-tumor activities. The protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). The protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

<Other activity>

The protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including,

height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution);
 effecting elimination of dietary fat, protein, carbohydrate;
 effecting behavioral characteristics, including appetite, libido, stress, cognition (including cognitive disorders), depression and violent behaviors;
 providing analgesic effects or other pain reducing effects;
 promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages;
 in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases.

The polypeptide with above activities, is suspected to have following functions by itself or interaction with its ligands or receptors or association with other molecules. For example, proliferation or cell death of B cells, T cells and/or mast cells or class specific induction of B cells by promotion of class switch of immunoglobulin genes; differentiation of B cells to antibody-forming cells; proliferation, differentiation, or cell death of precursors of granulocytes; proliferation, differentiation, or cell death of precursors of monocytes-macrophages;
 proliferation, of up regulation or cell death of neutrophils, monocytes-macrophages, eosinophils and/or basophils; proliferation, or cell death of precursors of megakaryocytes; proliferation, differentiation, or cell death of precursors of neutrophils; proliferation, differentiation, or cell death of precursors of T cells and B cells; promotion of production of erythrocytes; sustainment of proliferation of erythrocytes, neutrophils, eosinophils, basophils, monocytes-macrophages, mast cells, precursors of megakaryocyte ; promotion of migration of neutrophils, monocytes-

macrophages, B cells and/or T cells; proliferation or cell death of thymocytes; suppression of differentiation of adipocytes; proliferation or cell death of natural killer cells; proliferation or cell death of hematopoietic stem cells; suppression of proliferation of stem cells and each hematopoietic precursor cells; promotion of differentiation from mesenchymal stem cells to osteoblasts or chondrocytes, proliferation or cell death of mesenchymal stem cells, osteoblasts or chondrocytes and promotion of bone absorption by activation of osteoclasts and promotion of differentiation from monocytes to osteoclasts.

This peptide is also suspected to function to nervous system, so expected to have functions below; differentiation to kinds of neurotransmitter-responsive neurons, survival or cell death of these cells; promotion of proliferation or cell death of glial cells; spread of neural dendrites; survival or cell death of gangriocytes; proliferation, promotion of differentiation, or cell death of astrocytes; proliferation or survival of peripheral neurons; proliferation or cell death of Schwann cells; proliferation, survival or cell death of motoneurons.

Furthermore, in the process of development of early embryonic, this polypeptide is expected to promote or inhibit the organogenesis of epidermis, brain, backbone, and nervous system by induction of ectoderm, that of notochord connective tissues (bone, muscle, tendon), hemocytes, heart, kidney, and genital organs by induction of mesoderm, and that of digestive apparatus (stomach, intestine, liver, pancreas), respiratory apparatus (lung, trachea) by induction of endoderm. In adult, also, this polypeptide is thought to proliferate or inhibit the above organs.

Therefore, this polypeptide itself is expected to be used as an agent for the prevention or treatment of disease of progression or suppression of immune, nervous, or bone metabolic function, hypoplasia or overgrowth

of hematopoietic cells: inflammatory disease (rheumatism, ulcerative colitis, etc.), decrease of hematopoietic stem cells after bone marrow transplantation, decrease of leukocytes, platelets, B-cells, or T-cells after radiation exposure or chemotherapeutic dosage against cancer or leukemia, anemia, infectious disease, cancer, leukemia, AIDS, bone metabolic disease(osteoporosis etc.), arteriosclerosis, various degenerative disease (Alzheimer's disease, multiple sclerosis, etc.), or nervous lesion.

In addition, since this polypeptide is thought to induce the differentiation or growth of organs derived from ectoderm, mesoderm, and endoderm, this polypeptide is expected to be an agent for tissue repair (epidermis, bone, muscle, tendon, heart, kidney, stomach, intestine, liver, pancreas, lung, and trachea, etc.).

Quantitation of this polypeptide in the body can be performed using polyclonal or monoclonal antibodies against this polypeptide. It can be used the study of relationship between this polypeptide and disease or diagnosis of disease, and so on. Polyclonal and monoclonal antibodies can be prepared using this polypeptide or its fragment as an antigen by known method.

Identification, purification or molecular cloning of known or unknown proteins which bind this polypeptide can be performed using this polypeptide by, for example, preparation of the affinity-column.

Identification of the molecules which interact with this polypeptide and molecular cloning of the gene can be performed by west-western method using this polypeptide or by yeast two-hybrid system using the cDNA (preferably cDNA encoding this polypeptide).

Agonists/antagonists of this receptor polypeptide and inhibitors between receptor and signal transduction molecules can be screened using this polypeptide.

For example, the screening can be carried out the following method.

a) The reaction mixtures, which contain this polypeptide, screening compound and the cells, are incubated under the condition which the cells are normally stimulated by this peptide. (The reaction mixtures also contain the labeled compound, which is introduced into the cells according to the cell proliferation, and peptide which allow to observe the function of this peptide efficiently.)

b) Decision that the compounds are efficient agonists/antagonists or not, are performed by measurement of cell proliferation ability.

More detailed methods are followed:

Rat vascular muscle cell line (ATCC CRL-1444 or CRL1476) is cultured in 96 well plate with 10%FBS for 24 hours. Then the culture medium are replaced to the serum-free medium supplemented with each several concentrations of human PDGF-BB. At that time compounds to screen as well as A55 protein are added in the medium when screening the antagonists of A55 protein. While, compounds alone are added in the medium when screening the agonists of A55 protein. After 24 hours incubation, these cells are pulsed for 4hours with 3H-thymidine. By measuring the 3H-thymidine incorporation, it is possible to determine whether the compounds have inhibitory or stimulatory effect on the A55 activity.

cDNAs of the present invention are useful not only the important and essential template for the production of the polypeptide of the present invention which is expected to be largely useful, but also be useful for diagnosis or therapy (for example, treatment of gene lacking, treatment to stop the expression of the polypeptide by antisense DNA (RNA)).

Genomic DNA may be isolated with the cDNA of the present invention, as a probe. As the same manner, a mouse or human gene encoding which can be highly homologous to the cDNA of the present invention, that is, which encodes a polypeptide highly homologous to the polypeptide of the present

polyvinylpyrrolidone, magnesium metasilicate aluminate, etc.). The compositions may also comprise, as is normal practice, additional substances other than inert diluents: e.g. lubricating agents (such as magnesium stearate etc.), disintegrating agents (such as cellulose calcium glycolate, etc.), stabilizing agents (such as human serum albumin, lactose etc.), and assisting agents for dissolving (such as arginine, asparaginic acid etc.).

The tablets or pills may, if desired, be coated with a film of gastric or enteric materials (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate, etc.), or be coated with more than two films. And then, coating may include containment within capsules of absorbable materials such as gelatin.

Liquid compositions for oral administration include pharmaceutically-acceptable emulsions, solutions, syrups and elixirs. In such compositions, one or more of the active compound(s) is or are contained in inert diluent(s) commonly used (purified water, ethanol etc.). Besides inert diluents, such compositions may also comprise adjuvants (such as wetting agents, suspending agents, etc.), sweetening agents, flavoring agents, perfuming agents, and preserving agents.

Other compositions for oral administration include spray compositions which may be prepared by known methods and which comprise one or more of the active compound(s). Spray compositions may comprise additional substances other than inert diluents: e.g. stabilizing agents (sodium sulfite etc.), isotonic buffer (sodium chloride, sodium citrate, citric acid, etc.). For preparation of such spray compositions, for example, the method described in the United States Patent No. 2,868,691 or 3,095,355 (herein incorporated in their entireties by reference) may be used.

Injections for parenteral administration include sterile aqueous or

non-aqueous solutions, suspensions and emulsions. In such compositions, one or more active compound(s) is or are admixed with at least one inert aqueous diluent(s) (distilled water for injection, physiological salt solution, etc.) or inert non-aqueous diluents(s) (propylene glycol, polyethylene glycol, olive oil, ethanol, POLYSOLBATE 80 TM, etc.).

Injectations may comprise additional compound other than inert diluents: e.g. preserving agents, wetting agents, emulsifying agents, dispersing agents, stabilizing agent (such as human serum albumin, lactose, etc.), and assisting agents such as assisting agents for dissolving (arginine, asparaginic acid, etc.).

The Best Mode of the Invention

The following examples concerning clone A55 are illustrated, but not limit the present invention.

Example 1

Preparation of poly(A)+RNA

Total RNA was prepared from mouse day18.5 embryonic heart by TRIzol reagent (Trade Mark, GIBCOBRL), and poly (A)⁺ RNA was purified from the total RNA by mRNA Purification Kit (Trade Mark, Pharmacia).

Example 2

Preparation of yeast SST cDNA library

Double strand cDNA was synthesized by SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (brand name, GIBCOBRL) with above poly(A)+RNA as template and random 9mer as primer which was containing XhoI site:

5'-CGA TTG AAT TCT AGA CCT GCC TCG AGN NNN NNN NN-3' (SEQ ID NO. 16)

cdNA was ligated EcoRI adapter by DNA ligation kit ver.2 (trade name, Takara Shuzo; this kit was used in all ligating steps hereafter.) and digested by XhoI. cDNAs were separated by agarose-gel electrophoresis. 300 - 800 bp cDNAs were isolated and were ligated to EcoRI/NotI site of pSUC2 (see US 5,536,637). E. Coli DH10B strain were transformed by pSUC2 with electroporation to obtain yeast SST cDNA library.

Example 3

Screening by SST method and DNA sequencing of positive clone

Plasmids of the cDNA library were prepared. Yeast YTK12 strain were transformed by the plasmids with lithium acetate method (Current Protocols In Molecular Biology 13.7.1). The transformed yeast were plated on triptphan-free medium (CMD-Try medium) for selection. The plate was incubated for 48 hour at 30 oC. Replica of the colony which is obtained by Accutran Replica Plater (trade name, Schleicher & Schuell) were place YPR plate containing raffinose for carbon source, and the plate was incubated for 14 days at 30 oC.

After 3 days, each colony appeared was streaked on YPR plate again. The plates were incubated for 48 hours at 30 oC. Single colony was inoculated to YPR medium and was incubated for 48 hours at 30 oC. Then plasmids were prepared. Insert cDNA was amplified by PCR with two kind primers which exist end side of cloning site on pSUC2 (sense strand primers were biotinylated). Biotinylated single strand of cDNAs were purified with Dynabeads (trade name, DYNAL) and determined the nucleotide sequences.

Sequencing was performed by Dye Terminator Cycle Sequencing Ready Reaction with DNA Sequencing kit (trade name, Applied Biosystems Inc.) and sequence was determined by DNA sequencer 373 (Applied Biosystems Inc.). All

sequencing hereafter was carried with this method.

The clone named A55 is not registered on databases by homology search of cDNA sequence and deduced amino acid sequence and so it is cleared that the sequence is novel one. So, we tried to isolate clone full-length cDNA of the fragment of A55 clone (hereafter A55 SST fragment cDNA). We confirmed that A55 SST fragment cDNA contains signal peptide by comparison with known peptide which has signal peptide in view of function and structure.

Example 4

Cloning and sequencing of a full-length cDNA of A55

Phage particles of a cDNA library of mouse day13 embryonic heart (uni-ZAP XR, Stratagene) were transfected to E. coli XL1-Blue MRF* host cells (Stratagene). Obtained one million plaques were transferred to nylon membranes. The membranes were hybridized with ³²P-labeled mouse A55 SST fragment cDNA as a probe. Many positive plaques were obtained.

From one positive plaque the phage particles containing a cloned insert were prepared, and were subjected to conversion into phagemid particles (pBluescript SK(-)) by co-infection of E. coli XL1-Blue MRF* host cells (Stratagene) with ExAssist helper phage (Stratagene). The phagemid particles were transfected to E. coli DH5a. The plasmids were prepared from the obtained transformants.

Nucleotide sequence of 5'-end of cDNA were determined to confirm the existence of the sequences of SST fragment cDNA. And then full-length sequencing were performed to obtain SEQ ID NO.3.

An open reading frame was determined and translation region for amino acid sequence shown in SEQ ID NO. 2 and deduced full-length amino acid sequence shown in SEQ ID NO. 1 were obtained. Mature protein of the said polypeptide was deduced to 425 amino acids shown in SEQ ID NO. 3 (144..1418) or 423 amino

acids shown in SEQ ID NO. 4. Translation region of SEQ ID NO. 4 is shown in SEQ ID NO. 5.

It was confirmed that there was no identical sequences to the DNA of the present invention by homology search program, BLASTN and FASTA against public nucleotide database. And it was also confirmed that there were no identical sequences to the polypeptide of the present invention (mouse A55 protein) by homologue search program, BLASTX, BLASTP and FASTA against amino acid database.

It is revealed that the polypeptide of the present invention, mouse A55 is novel secretion protein since the polypeptide have no trans-membrane region by hydrophobisity analysis of the amino acid sequence.

It was revealed that A55 protein contained six EGF like domains by motif search, so it was expected that clone A55 also possesses EGF family like activities. Significant homology were also recognized between the amino acid sequence of clone mouse A55 (1-448 AA region) and the one of human S1-5 (SwissProt Accession No. HSU03877) (1-387 AA region) by the comparison using BLASTX, BLASTP and FASTA. It was reported that human S1-5 was a secreted protein containing EGF like domain, was induced in fibroblasts by growth arrest, and stimulated DNA synthesis (Beata Lecka-Czernik et. al. Mol. Cell. Biol. 15, 120-128, 1995). Farther it was revealed that A55 protein was homologous to many proteins containing EGF-like domain.

Example 5

Isolation of isoform gene of mouse A55 protein

Initiation coden was determined by cloning of 5'-end cDNA by 5'-RACE (Rapid Amplification of cDNA Ends method using Marathon cDNA Amplification Kit (trade name, Clontech). Double stranded cDNA template was prepared from poly(A)+RNA of mouse embryonic heart tissue. Primer mA55-R1:

5'- CGT TTG TGC ACT GCT GCT GTG CAT TCC -3' (SEQ ID NO. 17)

was prepared based on the information of full-length nucleotide sequences. PCR was performed with the said primer and adapter primer attached in the kit.

Amplified cDNA was separated with agarose-gel electrophoresis, and to pGEM-T Vector (trade name, Promega), ligated in and transformed to E. Coli DH5a and then plasmid was prepared. The full-length nucleotide sequences were determined. We found two deferent 5'-end sequences. One was identical to the clone containing the sequence in SEQ ID NO. 3, the other contained unknown sequence and no translational start site ATG (See SEQ ID NO. 7 and 8).

The region defined from exon 1 of the clone was replaced by another exon which exists 400 bp downstream region of exon 1 was clarified by gene analysis. So it was cleared that the clone shown in SEQ ID NO. 8 was generated by alternative splicing of exon 1. The clone encodes isoform protein shown in SEQ ID NO. 6 (6 amino acids in N termini of SEQ ID NO.1 was replaced by 19 amino acids in N termini of SEQ ID NO. 6).

The mature protein of this polypeptide was deduced 425 amino acids shown in SEQ ID NO. 8 (340...1614) or 423 amino acids shown in SEQ ID NO. 9. SEQ ID NO. 10 is the translational region of the polypeptide shown in SEQ ID NO. 9.

Example 6

Determination of nucleotide sequence of human A55 gene

The present inventors found that Human EST sequence (GENBANK Accession No. H17726) homologous to 5'-end sequence of mouse A55 in the process of

homology search shown in example 4.

And the present inventors buy the Clone ID 50483 derived from human brain cDNA library GENBANK Accession No. H17726 from American Type Culture Collection (ATCC). The full-length nucleotide sequence shown in SEQ ID NO. 13 was determined with the same manner as in the determination of mouse A55. Open reading frame was determined and translational region shown in SEQ ID NO. 12 and deduced amino acid sequence shown in SEQ ID NO. 11 were obtained.

From above results, it is clarified that the human clone is full-length and have 89.3 % homology to mouse A55 at DNA level (translational region) and have 94.2 % homology to the one at amino acid level. It is suggested that the obtained human clone should be human counterpart of mouse A55. (The clone was called human A55 hereafter.)

The mature protein of this polypeptide was deduced 425 amino acids shown in SEQ ID NO. 13 (238...1512) or 423 amino acids shown in SEQ ID NO. 14. Translational region of the polypeptide shown in SEQ ID NO. 14 shows in SEQ ID NO. 15.

It was confirmed that there was no identical sequences to the DNAs of the present invention by homology search program, BLASTN and FASTA against public nucleotide database. And it was also confirmed that there were no identical sequences to human A55 proteins by homologue search program, BLASTX, BLASTP and FASTA against amino acid database.

Example 7

Mouse A55 protein expression in mammalian cell

Mouse full-length cDNA shown in SEQ ID NO. 3 was inserted into expression vector for mammalian cell pNotS (Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991)) and mouse A55 expression plasmid pNotS-mA55 was constructed.

293T cells (which is derived from 293 cells (ATCC CRL-1573) and it stably transfected with SV40 T antigen) were transfected with pNotS and pNotS-mA55 using lipofection (GIBCOBRL). After preincubated for 19 hours, the cells were pulsed for 30 minutes with ^{35}S -Met in the Met-free medium. Then the cells were incubated in the medium containing Met for 5 hours. Supernatant of the cells was recovered and concentrated 10-fold using centricon-10 (trade name, AMICON). Samples were subjected to SDS-polyacrylamide-gel electrophoresis. The gel was dried and ^{35}S -labeled proteins were detected with BAS 2000 (Fuji Film).

A band was detected at 60-70 kDa in the supernatant of pNotS-mA55-transfected 293T cells. This band was not detected in the supernatant of pNotS-transfected 293T cells. This results confirmed that recombinant mouse A55 protein was expressed and secreted into the medium. Molecular weight (60-70 kDa) of this recombinant mouse A55 protein was greater than it (48 kDa) predicted from its amino acid sequences. As this protein had two potential N-linked glycosylation sites and many Ser and Thr residues in which O-linked glycosyl chain could be added, it was suggested that the mouse A55 protein was a glycoprotein.

Example 8

Measurement of inhibition on proliferation of rat vascular smooth muscle cells by mouse A55 protein

Vascular smooth muscle cells were isolated from rat aorta ranging from heart to diaphragm and cultured primarily by the methods described in Shin Seikagaku Jikken Kouza 10 (The Japanese Biochemical Society). These cells were co-incubated with 1, 3 or 10 ng/ml of human recombinant PDGF-BB (Genzyme) and 10% (v/v) of the mock or mA55 supernatant prepared according to the method described in example 7. And BrdU incorporation was measured using a Cell

Proliferation ELISA, BrdU colorimetric kit (Boehringer-Mannheim).

The supernatant from 293T cells transfected with pNotS-mA55 significantly inhibited BrdU incorporation of rat primary vascular smooth muscle cells, while the supernatant from 293T cells transfected with only pNotS show no effect as shown in Fig. 1.

Moreover the supernatant from 293T cells transfected with pNotS-mA55 also inhibited BrdU incorporation even when rat vascular smooth muscle cells were stimulated with 1, 3 or 10 ng/ml of PDGF and increased BrdU incorporation in a dose-dependent manner, whereas the supernatant from 293T cells transfected with only pNotS did not affect compared with no supernatant addition (See Fig. 1).

These data revealed that the recombinant mouse A55 protein had the growth inhibitory activity on vascular smooth muscle cells.

Example 9

Human A55 protein expression in mammalian cell

Human A55 expression plasmid, pNotS-hA55, was constructed by inserting human full-length cDNA shown in SEQ ID NO. 13 into was into expression vector for mammalian cell pNotS (Kaufman et al., Nucleic Acids Res. 19, 4485-4490 (1991)).

Cos1 cells were transfected with pNotS and pNotS-hA55 by lipofectin (GIBCOBRL). After preincubation for 24 hours, the cells were pulsed for 5 hours with ³⁵S-Met and ³⁵S-Cys. Supernatant of the cells was recovered and concentrated to 10-fold using centricon-10 (trade name, AMICON). Proteins in concentrated supernatant were separated by electrophoresis through SDS-page. The gel was dried and ³⁵S-labeled proteins were detected with BAS 2000 (Fuji Film).

A band was detected at 60-70 kDa in the supernatant from Cos1 cells

transfected with pNotS-hA55. This band was not detected in the supernatant of pNotS transfected Cos1 cells. These results confirmed that recombinant human A55 protein was expressed and secreted into the medium. And human A55 protein was also suggested that sugar chains were also added to human A55 protein as well as mouse A55.

Example 10

Detection of the inhibitory activity on proliferation of rat vascular smooth muscle cells by human A55 protein

A DNA fragment encoding a signal sequence of honey bee mertin, a tag sequence of six His residues and an enterokinase cleavage site was added to 5'-end of human A55 cDNA sequence from 238 to 1515 in SEQ ID NO. 13 or sequence in SEQ ID NO. 15 followed by stop codon and inserted into expression vector pNotS. Cos1 cells were transfected with pNotS-hA55 plasmid DNA and pNotS control plasmid DNA. The supernatant was recovered, digested by enterokinase, pulled through nickel column to remove the linker peptide, and then concentrated 10-fold by centricon-10 (trade name, AMICON).

After rat vascular muscle cell line (ATCC CRL-1444) was cultured in 96 well plates with 10% FBS for 24 hours, these cells were incubated for 24 hours with serum-free medium supplemented with several concentrations (1, 10 or 10 ng/ml) of human PDGF-BB (Genzyme) and with 10 % total volume of supernatant of Cos1 cells which were transfected with pNotS-hA55 or pNotS, and then were pulsed for 4 hours with 3H-thymidine. After harvesting 3H-thymidine incorporation was detected. In this cell line remarkable decrease of 3H-thymidine incorporation were observed by supplement with hA55 supernatant, while there was no effect in the presence of the control supernatant.

Moreover similar effects were also observed when using other rat

vascular smooth muscle cell lines (ATCC CRL-1476 and CRL-2018) and human vascular smooth muscle cell line (ATCC CRL-1999). These results revealed that the recombinant human A55 protein also had the growth inhibitory activity on the vascular smooth muscle cells as well as mouse A55 protein.

Morphological change was observed on the vascular smooth muscle cells treated with the supernatant from hA55-transfected Cos1 cells by microscopy detection. While no morphological change was observed on melanoma cell line SK-MEL-28 at the same experiment. Furthermore, hA55 protein was observed to induce the expression of chemokine JE and JK.

Experiment 11

Preparation of anti mouse A55 polyclonal antibody

Three kinds of peptide fragments of mouse A55 were synthesized by solid phase method:

RTNPVYRGPYSNPYSTSYSG (71-90) (48-67 of SEQ ID NO. 1)
 GAYYIFQIKSGNEGREFYMR (376-395) (353-372 of SEQ ID NO. 1)
 MTRPIKGPRDIQLDLEMITVN (406-426) (383-403 of SEQ ID NO. 1).

Rabbits were immunized to these peptides as immunogen and the serum were prepared after measurement of the activity. Each anti-mouse A55 antibody was purified by affinity column immobilized each peptide which was used as immunogen from the obtained serum.

The supernatant prepared by the same method described in example 7, was subjected to SDS-PAGE, the separated proteins were transferred to Immobilon-P (PVDF membrane, trade name, Millopore) from the acrylamide gel. After blocking the membranes they were incubated with the anti mouse A55 polyclonal antibody as the first antibody and by developing using ECL kit

(Amersham), the recombinant mouse A55 protein was detected.

A 60 k Da band was detected in the supernatant from mA55 transfected Cos1 cells as well as 35S-labeling experiment described in example 7. While no bands were detected in the supernatant from mock-transfected Cos1 cells. These results confirmed that the obtained polyclonal antibodies specifically recognized the mouse A55 protein.


Claims

1. Substantially purified form of the polypeptide that comprising the amino-acid sequence shown in SEQ ID NO. 11 or 14, homologue thereof, fragment thereof or homologue of the fragment.
2. A polypeptide according to claim 1 that consists (comprising) of the amino-acid sequence shown in SEQ ID NO. 11 or 14.
3. A cDNA encoding the polypeptide according to claim 1.
4. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. 12 or 15 or a fragment cDNA selectively hybridized to the cDNA.
5. A cDNA according to claim 3 that comprising the nucleotide sequence shown in SEQ ID NO. 13 or a fragment cDNA selectively hybridized to the cDNA.
6. A replication or expression vector carrying the cDNA according to claim 3 to 5.
7. A host cell transformed with the replication or expression vector according to claim 6.
8. A method for producing the polypeptide according to claim 1 or 2 which comprises culturing a host cell according to claim 7 under a condition effective to express the polypeptide according to claim 1 or 2.
9. A monoclonal or polyclonal antibody against the polypeptide according to claim 1 or 2.
10. A pharmaceutical composition containing the polypeptide according to claim 1 or 2 or the antibody according to claim 9, in association with pharmaceutically acceptable diluent and/or carrier.
11. A pharmaceutical composition for the treatment of abnormal growth of smooth muscle cell, containing a polypeptide according to claim 1 or 2, in association with a pharmaceutically acceptable diluent and/or

13. A screening method for an antagonist or agonist of the polypeptide according to claim 1 or 2 with using the said polypeptide.


09/674379

Fig. 1



09/674379

Fig. 2



09/674379

534 Rec'd PCT/PTO 30 OCT 2000

SEQUENCE LISTING

<110> Ono Pharmaceutical Co., Ltd.

<120> Novel polypeptides, cDNA coding these polypeptides and Use thereof

<130> ONF-2970PCT

<141> 1999-04-28

<150> JP 10-119731

<151> 1998-04-28

<160> 17

<170> PatentIn Ver. 2.0

<210> 1

<211> 448

<212> PRT

<213> Mus musculus

<400> 1

Met Pro Gly Leu Lys Arg Ile Leu Thr Val Thr Ile Leu Ala Leu Trp

-23 -20 -15 -10

Leu Pro His Pro Gly Asn Ala Gln Gln Gln Cys Thr Asn Gly Phe Asp

-5 1 5

Leu Asp Arg Gln Ser Gly Gln Cys Leu Asp Ile Asp Glu Cys Arg Thr
 10 15 20 25
 Ile Pro Glu Ala Cys Arg Gly Asp Met Met Cys Val Asn Gln Asn Gly
 30 35 40
 Gly Tyr Leu Cys Ile Pro Arg Thr Asn Pro Val Tyr Arg Gly Pro Tyr
 45 50 55
 Ser Asn Pro Tyr Ser Thr Ser Tyr Ser Gly Pro Tyr Pro Ala Ala Ala
 60 65 70
 Pro Pro Val Pro Ala Ser Asn Tyr Pro Thr Ile Ser Arg Pro Leu Val
 75 80 85
 Cys Arg Phe Gly Tyr Gln Met Asp Glu Gly Asn Gln Cys Val Asp Val
 90 95 100 105
 Asp Glu Cys Ala Thr Asp Ser His Gln Cys Asn Pro Thr Gln Ile Cys
 110 115 120
 Ile Asn Thr Glu Gly Gly Tyr Thr Cys Ser Cys Thr Asp Gly Tyr Trp
 125 130 135
 Leu Leu Glu Gly Gln Cys Leu Asp Ile Asp Glu Cys Arg Tyr Gly Tyr
 140 145 150
 Cys Gln Gln Leu Cys Ala Asn Val Pro Gly Ser Tyr Ser Cys Thr Cys
 155 160 165
 Asn Pro Gly Phe Thr Leu Asn Asp Asp Gly Arg Ser Cys Gln Asp Val
 170 175 180 185
 Asn Glu Cys Glu Thr Glu Asn Pro Cys Val Gln Thr Cys Val Asn Thr
 190 195 200
 Tyr Gly Ser Phe Ile Cys Arg Cys Asp Pro Gly Tyr Glu Leu Glu Glu
 205 210 215

Asp Gly Ile His Cys Ser Asp Met Asp Glu Cys Ser Phe Ser Glu Phe
 220 225 230
 Leu Cys Gln His Glu Cys Val Asn Gln Pro Gly Ser Tyr Phe Cys Ser
 235 240 245
 Cys Pro Pro Gly Tyr Val Leu Leu Asp Asp Asn Arg Ser Cys Gln Asp
 250 255 260 265
 Ile Asn Glu Cys Glu His Arg Asn His Thr Cys Thr Ser Leu Gln Thr
 270 275 280
 Cys Tyr Asn Leu Gln Gly Gly Phe Lys Cys Ile Asp Pro Ile Ser Cys
 285 290 295
 Glu Glu Pro Tyr Leu Leu Ile Gly Glu Asn Arg Cys Met Cys Pro Ala
 300 305 310
 Glu His Thr Ser Cys Arg Asp Gln Pro Phe Thr Ile Leu Tyr Arg Asp
 315 320 325
 Met Asp Val Val Ser Gly Arg Ser Val Pro Ala Asp Ile Phe Gln Met
 330 335 340 345
 Gln Ala Thr Thr Arg Tyr Pro Gly Ala Tyr Tyr Ile Phe Gln Ile Lys
 350 355 360
 Ser Gly Asn Glu Gly Arg Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile
 365 370 375
 Ser Ala Thr Leu Val Met Thr Arg Pro Ile Lys Gly Pro Arg Asp Ile
 380 385 390
 Gln Leu Asp Leu Glu Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg
 395 400 405
 Gly Ser Ser Val Ile Arg Leu Arg Ile Tyr Val Ser Gln Tyr Pro Phe
 410 415 420 425

<210> 2

<211> 1344

<212> DNA

<213> Mus musculus

<400> 2

```

atgccaggat taaaaaggat actcactgtt accatcttgg cactctgget tccacatect 60
gggaatgcac agcagcagtg cacaaacggc ttgacctgg accgccagtc aggacagtgt 120
ctagatattg atgaatgccg gaccatccct gaggcttgte gtggggacat gatgtgtgtc 180
aaccagaatg gcgggtatth gtgcatccct cgaaccaacc cagtgtatcg agggccttac 240
tcaaatecct actctacatc ctactcagge ccatacccag cagcggeccc accagtacca 300
gcttccaact accccacgat ttcaaggcct cttgtctgcc gctttgggta tcagatggat 360
gaaggcaacc agtgtgtgga tgtggacgag tgtgcaacag actcacacca gtgcaaccct 420
accagatct gtatcaacac tgaaggaggt tacacctgct cctgcaccga tgggtactgg 480
cttctggaag ggcagtgcct agatattgat gaatgtcgt atggttactg ccagcagctc 540
tgtgcaaatg ttccaggatc ctattcctgt acatgcaacc ctggtttcac cctcaacgac 600
gatggaaggt cttgccaaga tgtgaacgag tgcgaaactg agaateccctg tgttcagacc 660
tgtgtcaaca cctatggctc ttcatctgc cgtgtgacc caggatatga acttgaggaa 720
gatggcattc actgcagtga tatggacgag tgcagcttct ccgagttcct ctgtcaacac 780
gagtgtgtga accagccggg ctcatattc tgctcgtgcc ctccaggcta cgtcctgttg 840
gatgataacc gaagctgcca ggatatcaat gaatgtgagc accgaaacca cacgtgtacc 900
tcaactgcaga ctgtctacaa tctacaaggg ggttcaaatt gtattgatcc catcagctgt 960
gaggagcctt atctgctgat tggtgaaaac cgtgttatgt gtcctgctga gcacaccagc 1020
tgcagagacc agccattcac catcctgtat cgggacatgg atgtggtgtc aggacgtcc 1080

```

gttcctgctg acatcttcca gatgcaagca acaacccgat accctgggtgc ctattacatt 1140
ttccagatca aatctggcaa cgagggtcga gagttctata tgcggcaaac agggcctatc 1200
agtgccaccc tggatgatgac acgccccatc aaagggcctc gggacatcca gctggacttg 1260
gagatgatca ctgtcaacac tgtcatcaac ttcagaggca gtcctgtgat ccgactgcgg 1320
atatatgtgt cgcagtatcc gtgc 1344

<210> 3

<211> 2233

<212> DNA

<213> Mus musculus

<220>

<223> Clone mouse A55 derived from Day 13 mouse embryonic heart

<220>

<221> CDS

<222> (75)..(1418)

<220>

<221> sig_peptide

<222> (75)..(143)

<220>

<221> mat_peptide

<222> (144)..(1418)

<400> 3

aattcggcac gagccccagt cccaccgcag agcctgcctt cctcgcgtcg cttctcctcc 60
cgcgcatcctt ggat atg cca gga tta aaa agg ata ctc act gtt acc atc 110

Met Pro Gly Leu Lys Arg Ile Leu Thr Val Thr Ile

-20

-15

ttg gca ctc tgg ctt cca cat cct ggg aat gca cag cag cag tgc aca 158
Leu Ala Leu Trp Leu Pro His Pro Gly Asn Ala Gln Gln Gln Cys Thr

-10

-5

-1

1

5

aac ggc ttt gac ctg gac cgc cag tca gga cag tgt cta gat att gat 206
Asn Gly Phe Asp Leu Asp Arg Gln Ser Gly Gln Cys Leu Asp Ile Asp

10

15

20

gaa tgc cgg acc atc cct gag gct tgt cgt ggg gac atg atg tgt gtc 254
Glu Cys Arg Thr Ile Pro Glu Ala Cys Arg Gly Asp Met Met Cys Val

25

30

35

aac cag aat ggc ggg tat ttg tgc atc cct cga acc aac cca gtg tat 302
Asn Gln Asn Gly Gly Tyr Leu Cys Ile Pro Arg Thr Asn Pro Val Tyr

40

45

50

cga ggg cct tac tca aat ccc tac tct aca tcc tac tca ggc cca tac 350
Arg Gly Pro Tyr Ser Asn Pro Tyr Ser Thr Ser Tyr Ser Gly Pro Tyr

55

60

65

cca gca gcg gcc cca cca gta cca gct tcc aac tac ccc acg att tca 398
Pro Ala Ala Ala Pro Pro Val Pro Ala Ser Asn Tyr Pro Thr Ile Ser

70

75

80

85

agg cct ctt gtc tgc cgc ttt ggg tat cag atg gat gaa ggc aac cag 446
Arg Pro Leu Val Cys Arg Phe Gly Tyr Gln Met Asp Glu Gly Asn Gln

90	95	100	
tgt gtg gat gtg gac gag tgt gca aca gac tca cac cag tgc aac cct	494		
Cys Val Asp Val Asp Glu Cys Ala Thr Asp Ser His Gln Cys Asn Pro			
105	110	115	
acc cag atc tgt atc aac act gaa gga ggt tac acc tgc tcc tgc acc	542		
Thr Gln Ile Cys Ile Asn Thr Glu Gly Gly Tyr Thr Cys Ser Cys Thr			
120	125	130	
gat ggg tac tgg ctt ctg gaa ggg cag tgc cta gat att gat gaa tgt	590		
Asp Gly Tyr Trp Leu Leu Glu Gly Gln Cys Leu Asp Ile Asp Glu Cys			
135	140	145	
cgc tat ggt tac tgc cag cag ctc tgt gca aat gtt cca gga tcc tat	638		
Arg Tyr Gly Tyr Cys Gln Gln Leu Cys Ala Asn Val Pro Gly Ser Tyr			
150	155	160	165
tcc tgt aca tgc aac cct ggt ttc acc ctc aac gac gat gga agg tct	686		
Ser Cys Thr Cys Asn Pro Gly Phe Thr Leu Asn Asp Asp Gly Arg Ser			
170	175	180	
tgc caa gat gtg aac gag tgc gaa act gag aat ccc tgt gtt cag acc	734		
Cys Gln Asp Val Asn Glu Cys Glu Thr Glu Asn Pro Cys Val Gln Thr			
185	190	195	
tgt gtc aac acc tat ggc tct ttc atc tgc cgc tgt gac cca gga tat	782		
Cys Val Asn Thr Tyr Gly Ser Phe Ile Cys Arg Cys Asp Pro Gly Tyr			
200	205	210	
gaa ctt gag gaa gat ggc att cac tgc agt gat atg gac gag tgc agc	830		
Glu Leu Glu Glu Asp Gly Ile His Cys Ser Asp Met Asp Glu Cys Ser			
215	220	225	
ttc tcc gag ttc ctc tgt caa cac gag tgt gtg aac cag ccg ggc tca	878		

Phe Ser Glu Phe Leu Cys Gln His Glu Cys Val Asn Gln Pro Gly Ser
 230 235 240 245
 tac ttc tgc tgc tgc cct cca ggc tac gtc ctg ttg gat gat aac cga 926
 Tyr Phe Cys Ser Cys Pro Pro Gly Tyr Val Leu Leu Asp Asp Asn Arg
 250 255 260
 agc tgc cag gat atc aat gaa tgt gag cac cga aac cac acg tgt acc 974
 Ser Cys Gln Asp Ile Asn Glu Cys Glu His Arg Asn His Thr Cys Thr
 265 270 275
 tca ctg cag act tgc tac aat cta caa ggg ggc ttc aaa tgt att gat 1022
 Ser Leu Gln Thr Cys Tyr Asn Leu Gln Gly Gly Phe Lys Cys Ile Asp
 280 285 290
 ccc atc agc tgt gag gag cct tat ctg ctg att ggt gaa aac cgc tgt 1070
 Pro Ile Ser Cys Glu Glu Pro Tyr Leu Leu Ile Gly Glu Asn Arg Cys
 295 300 305
 atg tgt cct gct gag cac acc agc tgc aga gac cag cca ttc acc atc 1118
 Met Cys Pro Ala Glu His Thr Ser Cys Arg Asp Gln Pro Phe Thr Ile
 310 315 320 325
 ctg tat cgg gac atg gat gtg gtg tca gga cgc tcc gtt cct gct gac 1166
 Leu Tyr Arg Asp Met Asp Val Val Ser Gly Arg Ser Val Pro Ala Asp
 330 335 340
 atc ttc cag atg caa gca aca acc cga tac cct ggt gcc tat tac att 1214
 Ile Phe Gln Met Gln Ala Thr Thr Arg Tyr Pro Gly Ala Tyr Tyr Ile
 345 350 355
 ttc cag atc aaa tct ggc aac gag ggt cga gag ttc tat atg cgg caa 1262
 Phe Gln Ile Lys Ser Gly Asn Glu Gly Arg Glu Phe Tyr Met Arg Gln
 360 365 370

aca ggg cct atc agt gcc acc ctg gtg atg aca cgc ccc atc aaa ggg 1310
 Thr Gly Pro Ile Ser Ala Thr Leu Val Met Thr Arg Pro Ile Lys Gly
 375 380 385
 cct cgg gac atc cag ctg gac ttg gag atg atc act gtc aac act gtc 1358
 Pro Arg Asp Ile Gln Leu Asp Leu Glu Met Ile Thr Val Asn Thr Val
 390 395 400 405
 atc aac ttc aga ggc agc tcc gtg atc cga ctg cgg ata tat gtg tcg 1406
 Ile Asn Phe Arg Gly Ser Ser Val Ile Arg Leu Arg Ile Tyr Val Ser
 410 415 420
 cag tat ccg ttc tgagcctctg gctaaggcct ctgacactgc ctttcaccag 1458
 Gln Tyr Pro Phe
 425
 caccgaggga cgggaggaga aaggaaacca gcaagaatga gagcgagaca gacattgcac 1518
 ctttctctgct gaatatctcc tgggggcac agcctagcat cttgacccat atctgtacta 1578
 ttgcagatgg tcaactctgaa ggacaccctg ccctcagttc ctatgatgca gttatccaaa 1638
 agtgttcac ttagccccctg atatgagggt gccagtgact cttcaaagcc ttccatttat 1698
 ttccatcggt ttataaaaaa gaaaatagat tagatttgct ggggtatgag tctctgaagg 1758
 ttcaaaagac tgagtggcct gctctcacct ctctctctcc tctctccate tcttgctgca 1818
 ttgctgcttt gcaaaagtcc tcatgggctc gtgggaaatg ctgggaatag ctagtgtgct 1878
 tcttgcatgt tctgagaagg ctatgggaac acaccacagc aggatcgaag gtttttatag 1938
 agtctatttt aaaatcacat ctggtatttt cagcataaaa gaaattttag ttgtctttaa 1998
 aatttgatg agtggtttaa cttttcttat tcattttgag gcttcttaaa gtggtagaat 2058
 tctttccaaa ggctcagat acatgttatg ttcagtcttt ccaacctcat ctttctctgc 2118
 atcttagccc agtttttaag aagaccctt aatcatgctt tnttaagagt ttttacccaa 2178
 ctgcgttgga agacagaggt atccagactg attaaataat tgaagaaaaa aaaaa 2233

<210> 4

<211> 423

<212> PRT

<213> Mus musculus

<400> 4

Gln Cys Thr Asn Gly Phe Asp Leu Asp Arg Gln Ser Gly Gln Cys Leu

1 5 10 15

Asp Ile Asp Glu Cys Arg Thr Ile Pro Glu Ala Cys Arg Gly Asp Met

20 25 30

Met Cys Val Asn Gln Asn Gly Gly Tyr Leu Cys Ile Pro Arg Thr Asn

35 40 45

Pro Val Tyr Arg Gly Pro Tyr Ser Asn Pro Tyr Ser Thr Ser Tyr Ser

50 55 60

Gly Pro Tyr Pro Ala Ala Ala Pro Pro Val Pro Ala Ser Asn Tyr Pro

65 70 75 80

Thr Ile Ser Arg Pro Leu Val Cys Arg Phe Gly Tyr Gln Met Asp Glu

85 90 95

Gly Asn Gln Cys Val Asp Val Asp Glu Cys Ala Thr Asp Ser His Gln

100 105 110

Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr Glu Gly Gly Tyr Thr Cys

115 120 125

Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu Gly Gln Cys Leu Asp Ile

130 135 140

Asp Glu Cys Arg Tyr Gly Tyr Cys Gln Gln Leu Cys Ala Asn Val Pro

145	150	155	160
Gly Ser Tyr Ser Cys Thr Cys Asn Pro Gly Phe Thr Leu Asn Asp Asp			
	165	170	175
Gly Arg Ser Cys Gln Asp Val Asn Glu Cys Glu Thr Glu Asn Pro Cys			
	180	185	190
Val Gln Thr Cys Val Asn Thr Tyr Gly Ser Phe Ile Cys Arg Cys Asp			
	195	200	205
Pro Gly Tyr Glu Leu Glu Glu Asp Gly Ile His Cys Ser Asp Met Asp			
	210	215	220
Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln His Glu Cys Val Asn Gln			
225	230	235	240
Pro Gly Ser Tyr Phe Cys Ser Cys Pro Pro Gly Tyr Val Leu Leu Asp			
	245	250	255
Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu Cys Glu His Arg Asn His			
	260	265	270
Thr Cys Thr Ser Leu Gln Thr Cys Tyr Asn Leu Gln Gly Gly Phe Lys			
	275	280	285
Cys Ile Asp Pro Ile Ser Cys Glu Glu Pro Tyr Leu Leu Ile Gly Glu			
	290	295	300
Asn Arg Cys Met Cys Pro Ala Glu His Thr Ser Cys Arg Asp Gln Pro			
305	310	315	320
Phe Thr Ile Leu Tyr Arg Asp Met Asp Val Val Ser Gly Arg Ser Val			
	325	330	335
Pro Ala Asp Ile Phe Gln Met Gln Ala Thr Thr Arg Tyr Pro Gly Ala			
	340	345	350
Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn Glu Gly Arg Glu Phe Tyr			

355 360 365
 Met Arg Gln Thr Gly Pro Ile Ser Ala Thr Leu Val Met Thr Arg Pro
 370 375 380
 Ile Lys Gly Pro Arg Asp Ile Gln Leu Asp Leu Glu Met Ile Thr Val
 385 390 395 400
 Asn Thr Val Ile Asn Phe Arg Gly Ser Ser Val Ile Arg Leu Arg Ile
 405 410 415
 Tyr Val Ser Gln Tyr Pro Phe
 420

<210> 5

<211> 1269

<212> DNA

<213> Mus musculus

<400> 5

cagtgcacaa acggctttga cctggaccgc cagtcaggac agtgtctaga tattgatgaa 60
 tgccggacca tccctgaggc ttgtcgtggg gacatgatgt gtgtcaacca gaatggcggg 120
 tatttgtgca tccctogaac caaccagtg tategagggc cttactcaaa tccctactct 180
 acatcctact caggcccata cccagcagcg gcccaccag taccagcttc caactacccc 240
 acgatttcaa ggcctcttgt ctgccgcttt gggtatcaga tggatgaagg caaccagtgt 300
 gtggatgtgg acgagtgtgc aacagactca caccagtgc accctaccca gatctgtatc 360
 aacactgaag gaggttacac ctgctcctgc accgatgggt actggcttct ggaagggcag 420
 tgccatagata ttgatgaatg tcgctatggg tactgccagc agctctgtgc aaatgttcca 480
 ggatcctatt cctgtacatg caaccctggg ttcacctca acgacgatgg aaggtcttgc 540

caagatgtga acgagtgcga aactgagaat cctgtgttc agacctgtgt caacacctat 600
 ggctctttca tctgccgctg tgaccagga tatgaacttg aggaagatgg cattcactgc 660
 agtgatatgg acgagtgcag ctctccgag ttctctgtc aacacgagtg tgtgaaccag 720
 ccgggctcat acttctgtc gtgcccctca ggctacgtcc tgttgatga taaccgaagc 780
 tgccaggata tcaatgaatg tgagcaccga aaccacacgt gtacctcact gcagacttgc 840
 tacaatctac aagggggctt caaatgtatt gatcccatca gctgtgagga gccttatctg 900
 ctgattggtg aaaaccgctg tatgtgtcct gctgagcaca ccagctgcag agaccagcca 960
 ttcccatcc tgtatcgga catggatgtg gtgtcaggac gctccgttcc tgttgacatc 1020
 ttccagatgc aagcaacaac ccgataccct ggtgcctatt acattttcca gatcaaactc 1080
 ggcaacgagg gtcgagagtt ctatatggc caaacagggc ctatcagtgc caccctggtg 1140
 atgacacgcc ccatcaaagg gctcgggac atccagctgg acttgagat gatcactgtc 1200
 aacactgtca tcaacttcag aggcagctcc gtgatccgac tgcggatata tgtgtcgcag 1260
 tatecgttc 1269

<210> 6

<211> 461

<212> PRT

<213> Mus musculus

<400> 6

Met Gly Pro Arg Ser Phe Glu Pro Met His Ser Gly Leu Cys Arg Gln

-35

-30

-25

Arg Arg Met Ile Leu Thr Val Thr Ile Leu Ala Leu Trp Leu Pro His

-20

-15

-10

-5

Pro Gly Asn Ala Gln Gln Gln Cys Thr Asn Gly Phe Asp Leu Asp Arg

-1	1	5	10
Gln Ser Gly Gln Cys Leu Asp Ile Asp Glu Cys Arg Thr Ile Pro Glu			
15	20	25	
Ala Cys Arg Gly Asp Met Met Cys Val Asn Gln Asn Gly Gly Tyr Leu			
30	35	40	
Cys Ile Pro Arg Thr Asn Pro Val Tyr Arg Gly Pro Tyr Ser Asn Pro			
45	50	55	60
Tyr Ser Thr Ser Tyr Ser Gly Pro Tyr Pro Ala Ala Ala Pro Pro Val			
	65	70	75
Pro Ala Ser Asn Tyr Pro Thr Ile Ser Arg Pro Leu Val Cys Arg Phe			
	80	85	90
Gly Tyr Gln Met Asp Glu Gly Asn Gln Cys Val Asp Val Asp Glu Cys			
	95	100	105
Ala Thr Asp Ser His Gln Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr			
	110	115	120
Glu Gly Gly Tyr Thr Cys Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu			
125	130	135	140
Gly Gln Cys Leu Asp Ile Asp Glu Cys Arg Tyr Gly Tyr Cys Gln Gln			
	145	150	155
Leu Cys Ala Asn Val Pro Gly Ser Tyr Ser Cys Thr Cys Asn Pro Gly			
	160	165	170
Phe Thr Leu Asn Asp Asp Gly Arg Ser Cys Gln Asp Val Asn Glu Cys			
	175	180	185
Glu Thr Glu Asn Pro Cys Val Gln Thr Cys Val Asn Thr Tyr Gly Ser			
	190	195	200
Phe Ile Cys Arg Cys Asp Pro Gly Tyr Glu Leu Glu Glu Asp Gly Ile			

205	210	215	220
His Cys Ser Asp Met Asp Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln			
	225	230	235
His Glu Cys Val Asn Gln Pro Gly Ser Tyr Phe Cys Ser Cys Pro Pro			
	240	245	250
Gly Tyr Val Leu Leu Asp Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu			
	255	260	265
Cys Glu His Arg Asn His Thr Cys Thr Ser Leu Gln Thr Cys Tyr Asn			
	270	275	280
Leu Gln Gly Gly Phe Lys Cys Ile Asp Pro Ile Ser Cys Glu Glu Pro			
285	290	295	300
Tyr Leu Leu Ile Gly Glu Asn Arg Cys Met Cys Pro Ala Glu His Thr			
	305	310	315
Ser Cys Arg Asp Gln Pro Phe Thr Ile Leu Tyr Arg Asp Met Asp Val			
	320	325	330
Val Ser Gly Arg Ser Val Pro Ala Asp Ile Phe Gln Met Gln Ala Thr			
	335	340	345
Thr Arg Tyr Pro Gly Ala Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn			
	350	355	360
Glu Gly Arg Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile Ser Ala Thr			
365	370	375	380
Leu Val Met Thr Arg Pro Ile Lys Gly Pro Arg Asp Ile Gln Leu Asp			
	385	390	395
Leu Glu Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg Gly Ser Ser			
	400	405	410
Val Ile Arg Leu Arg Ile Tyr Val Ser Gln Tyr Pro Phe			

415

420

425

<210> 7

<211> 1383

<212> DNA

<213> Mus musculus

<400> 7

atgggaccta gaagtttcga gccaatgcac agtggactct gcagacagag acgcatgata 60
ctcactgtta ccatcttggc actctggctt ccacatcctg ggaatgcaca gcagcagtgc 120
acaaacggct ttgacctgga ccgccagtca ggacagtgtc tagatattga tgaatgccgg 180
accatccctg aggcttgtcg tggggacatg atgtgtgtca accagaatgg cgggtatttg 240
tgcateccctc gaaccaaccc agtgtatcga gggccttact caaatcccta ctctacatcc 300
tactcaggcc catacccagc agcggcccca ccagtaccag cttccaacta ccccacgatt 360
tcaaggcctc ttgtctgccg ctttgggtat cagatggatg aaggcaacca gtgtgtggat 420
gtggacgagt gtgcaacaga ctcacaccag tgcaacccta ccagatctg tatcaacact 480
gaaggagggt acacctgctc ctgcaccgat gggacttggc ttctggaagg gcagtgccta 540
gatattgatg aatgtcgcta tggttactgc cagcagctct gtgcaaagt tccaggatcc 600
tattcctgta catgcaaccc tggtttcacc ctcaacgacg atggaaggtc ttgccaagat 660
gtgaacgagt gcgaaactga gaatccctgt gttcagacct gtgtcaacac ctatggctct 720
ttcatctgcc gctgtgaccc aggatatgaa cttgaggaag atggcattca ctgcagtgat 780
atggacgagt gcagcttctc cgagttctc tgtcaacacg agtgtgtgaa ccagccgggc 840
tcatacttct gctcgtgccc tccaggetac gtcctgttgg atgataaccg aagctgccag 900
gatatcaatg aatgtgagca ccgaaaccac acgtgtacct cactgcagac ttgtacaat 960
ctacaagggg gcttcaaagt tattgatccc atcagctgtg aggagcctta tctgctgatt 1020

ggtgaaaacc gctgtatgtg tectgtgtgag cacaccagct gcagagacca gccattcacc 1080
 atcctgtatc gggacatgga tgtgggtgtca ggacgtccg ttcctgtga catcttccag 1140
 atgcaagcaa caacccgata ccttgggtgcc tattacattt tccagatcaa atctggcaac 1200
 gagggtcgag agttctatat gcggcaaaca gggcctatca gtgccaccct ggtgatgaca 1260
 cgccccatca aagggcctcg ggacatccag ctggacttgg agatgatcac tgtcaacact 1320
 gtcacaaact tcagaggcag ctccgtgatc cgactgcgga tatatgtgtc gcaglatccg 1380
 ttc 1383

<210> 8

<211> 2429

<212> DNA

<213> Mus musculus

<220>

<223> Clone mouse A55b derived from Day 13 mouse embryonic heart

<220>

<221> CDS

<222> (232).. (1614)

<220>

<221> sig_peptide

<222> (232).. (339)

<220>

Pro Arg Thr Asn Pro Val Tyr Arg Gly Pro Tyr Ser Asn Pro Tyr Ser
 50 55 60
 aca tcc tac tca ggc cca tac cca gca ggc gcc cca cca gta cca gct 573
 Thr Ser Tyr Ser Gly Pro Tyr Pro Ala Ala Ala Pro Pro Val Pro Ala
 65 70 75
 tcc aac tac ccc acg att tca agg cct ctt gtc tgc cgc ttt ggg tat 621
 Ser Asn Tyr Pro Thr Ile Ser Arg Pro Leu Val Cys Arg Phe Gly Tyr
 80 85 90
 cag atg gat gaa ggc aac cag tgt gtg gat gtg gac gag tgt gca aca 669
 Gln Met Asp Glu Gly Asn Gln Cys Val Asp Val Asp Glu Cys Ala Thr
 95 100 105 110
 gac tca cac cag tgc aac cct acc cag atc tgt atc aac act gaa gga 717
 Asp Ser His Gln Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr Glu Gly
 115 120 125
 ggt tac acc tgc tcc tgc acc gat ggg tac tgg ctt ctg gaa ggg cag 765
 Gly Tyr Thr Cys Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu Gly Gln
 130 135 140
 tgc cta gat att gat gaa tgt cgc tat ggt tac tgc cag cag ctc tgt 813
 Cys Leu Asp Ile Asp Glu Cys Arg Tyr Gly Tyr Cys Gln Gln Leu Cys
 145 150 155
 gca aat gtt cca gga tcc tat tcc tgt aca tgc aac cct ggt ttc acc 861
 Ala Asn Val Pro Gly Ser Tyr Ser Cys Thr Cys Asn Pro Gly Phe Thr
 160 165 170
 ctc aac gac gat gga agg tct tgc caa gat gtg aac gag tgc gaa act 909
 Leu Asn Asp Asp Gly Arg Ser Cys Gln Asp Val Asn Glu Cys Glu Thr
 175 180 185 190

gag aat ccc tgt gtt cag acc tgt gtc aac acc tat ggc tct ttc atc 957

Glu Asn Pro Cys Val Gln Thr Cys Val Asn Thr Tyr Gly Ser Phe Ile

195

200

205

tgc cgc tgt gac cca gga tat gaa ctt gag gaa gat ggc att cac tgc 1005

Cys Arg Cys Asp Pro Gly Tyr Glu Leu Glu Glu Asp Gly Ile His Cys

210

215

220

agt gat atg gac gag tgc agc ttc tcc gag ttc ctc tgt caa cac gag 1053

Ser Asp Met Asp Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln His Glu

225

230

235

tgt gtg aac cag ccg ggc tca tac ttc tgc tgc tgc cct cca ggc tac 1101

Cys Val Asn Gln Pro Gly Ser Tyr Phe Cys Ser Cys Pro Pro Gly Tyr

240

245

250

gtc ctg ttg gat gat aac cga agc tgc cag gat atc aat gaa tgt gag 1149

Val Leu Leu Asp Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu Cys Glu

255

260

265

270

cac cga aac cac acg tgt acc tca ctg cag act tgc tac aat cta caa 1197

His Arg Asn His Thr Cys Thr Ser Leu Gln Thr Cys Tyr Asn Leu Gln

275

280

285

ggg ggc ttc aaa tgt att gat ccc atc agc tgt gag gag cct tat ctg 1245

Gly Gly Phe Lys Cys Ile Asp Pro Ile Ser Cys Glu Glu Pro Tyr Leu

290

295

300

ctg att ggt gaa aac cgc tgt atg tgt cct gct gag cac acc agc tgc 1293

Leu Ile Gly Glu Asn Arg Cys Met Cys Pro Ala Glu His Thr Ser Cys

305

310

315

aga gac cag cca ttc acc atc ctg tat cgg gac atg gat gtg gtg tca 1341

Arg Asp Gln Pro Phe Thr Ile Leu Tyr Arg Asp Met Asp Val Val Ser

320 325 330
 gga cgc tcc gtt cct gct gac atc ttc cag atg caa gca aca acc cga 1389
 Gly Arg Ser Val Pro Ala Asp Ile Phe Gln Met Gln Ala Thr Thr Arg
 335 340 345 350
 tac cct ggt gcc tat tac att ttc cag atc aaa tct ggc aac gag ggt 1437
 Tyr Pro Gly Ala Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn Glu Gly
 355 360 365
 cga gag ttc tat atg cgg caa aca ggg cct atc agt gcc acc ctg gtg 1485
 Arg Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile Ser Ala Thr Leu Val
 370 375 380
 atg aca cgc ccc atc aaa ggg cct cgg gac atc cag ctg gac ttg gag 1533
 Met Thr Arg Pro Ile Lys Gly Pro Arg Asp Ile Gln Leu Asp Leu Glu
 385 390 395
 atg atc act gtc aac act gtc atc aac ttc aga ggc agc tcc gtg atc 1581
 Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg Gly Ser Ser Val Ile
 400 405 410
 cga ctg cgg ata tat gtg tgc cag tat ccg ttc tgagcctctg gctaaggcct 1634
 Arg Leu Arg Ile Tyr Val Ser Gln Tyr Pro Phe
 415 420 425
 ctgacactgc ctttcaccag caccgaggga cgggaggaga aaggaaacca gcaagaatga 1694
 gagcgagaca gacattgcac ctttcctgct gaatatctcc tgggggcac agcctagcat 1754
 cttgacccat atctgtacta ttgcagatgg tcaactctgaa ggacaccctg ccctcagttc 1814
 ctatgatgca gttatccaaa agtggttcac ttageccctg atatgaggtt gccagtgact 1874
 cttcaaagcc ttccatttat ttccatcggt ttataaaaaa gaaaatagat tagatttgct 1934
 ggggtatgag tctcgaagg ttcaaaagac tgagtggctt gctctcacct cttcctctcc 1994
 ttctccatc tcttgctgca ttgctgcttt gcaaaagtcc tcatgggctc gtgggaaatg 2054

ctgggaatag ctagtgttgc tcttgcatgt tctgagaagg ctatgggaac acaccacagc 2114
 aggatcgaag gtttttatag agtctatgtt aaaatcacat ctggtatgtt cagcataaaa 2174
 gaaatttttag ttgtctttaa aatttgatg agtgtttaac cttttcttat tcattttgag 2234
 gcttcttaaa gtggtagaat tccttccaaa ggcctcagat acatgttatg ttcagtcttt 2294
 ccaacctcat cctttcctgc atcttagccc agtttttacg aagacccctt aatcatgctt 2354
 tnttaagagt ttttacccaa ctgcgttgga agacagaggt atccagactg attaaataat 2414
 tgaagaaaaa aaaaaa 2429

<210> 9

<211> 423

<212> PRT

<213> Mus musculus

<400> 9

Gln	Cys	Thr	Asn	Gly	Phe	Asp	Leu	Asp	Arg	Gln	Ser	Gly	Gln	Cys	Leu
1				5						10				15	
Asp	Ile	Asp	Glu	Cys	Arg	Thr	Ile	Pro	Glu	Ala	Cys	Arg	Gly	Asp	Met
			20							25				30	
Met	Cys	Val	Asn	Gln	Asn	Gly	Gly	Tyr	Leu	Cys	Ile	Pro	Arg	Thr	Asn
			35							40				45	
Pro	Val	Tyr	Arg	Gly	Pro	Tyr	Ser	Asn	Pro	Tyr	Ser	Thr	Ser	Tyr	Ser
			50							55				60	
Gly	Pro	Tyr	Pro	Ala	Ala	Ala	Pro	Pro	Val	Pro	Ala	Ser	Asn	Tyr	Pro
			65							70				75	
Thr	Ile	Ser	Arg	Pro	Leu	Val	Cys	Arg	Phe	Gly	Tyr	Gln	Met	Asp	Glu

	85		90		95
Gly Asn Gln Cys Val Asp Val Asp Glu Cys Ala Thr Asp Ser His Gln					
	100		105		110
Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr Glu Gly Gly Tyr Thr Cys					
	115		120		125
Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu Gly Gln Cys Leu Asp Ile					
	130		135		140
Asp Glu Cys Arg Tyr Gly Tyr Cys Gln Gln Leu Cys Ala Asn Val Pro					
	145		150		155
Gly Ser Tyr Ser Cys Thr Cys Asn Pro Gly Phe Thr Leu Asn Asp Asp					
	165		170		175
Gly Arg Ser Cys Gln Asp Val Asn Glu Cys Glu Thr Glu Asn Pro Cys					
	180		185		190
Val Gln Thr Cys Val Asn Thr Tyr Gly Ser Phe Ile Cys Arg Cys Asp					
	195		200		205
Pro Gly Tyr Glu Leu Glu Glu Asp Gly Ile His Cys Ser Asp Met Asp					
	210		215		220
Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln His Glu Cys Val Asn Gln					
	225		230		235
Pro Gly Ser Tyr Phe Cys Ser Cys Pro Pro Gly Tyr Val Leu Leu Asp					
	245		250		255
Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu Cys Glu His Arg Asn His					
	260		265		270
Thr Cys Thr Ser Leu Gln Thr Cys Tyr Asn Leu Gln Gly Gly Phe Lys					
	275		280		285
Cys Ile Asp Pro Ile Ser Cys Glu Glu Pro Tyr Leu Leu Ile Gly Glu					

290	295	300	
Asn Arg Cys Met Cys Pro Ala Glu His Thr Ser Cys Arg Asp Gln Pro			
305	310	315	320
Phe Thr Ile Leu Tyr Arg Asp Met Asp Val Val Ser Gly Arg Ser Val			
	325	330	335
Pro Ala Asp Ile Phe Gln Met Gln Ala Thr Thr Arg Tyr Pro Gly Ala			
	340	345	350
Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn Glu Gly Arg Glu Phe Tyr			
	355	360	365
Met Arg Gln Thr Gly Pro Ile Ser Ala Thr Leu Val Met Thr Arg Pro			
	370	375	380
Ile Lys Gly Pro Arg Asp Ile Gln Leu Asp Leu Glu Met Ile Thr Val			
385	390	395	400
Asn Thr Val Ile Asn Phe Arg Gly Ser Ser Val Ile Arg Leu Arg Ile			
	405	410	415
Tyr Val Ser Gln Tyr Pro Phe			
	420		

<210> 10

<211> 1269

<212> DNA

<213> Mus musculus

<400> 10

cagtgcacaa acggtttga cctggaccgc cagtcaggac agtgtctaga tattgatgaa 60

2014年12月15日

$\langle 210 \rangle$	11
$\langle 211 \rangle$	448
$\langle 212 \rangle$	PRT

155	160	165	
Asn Pro Gly Phe Thr Leu Asn Glu Asp Gly Arg Ser Cys Gln Asp Val			
170	175	180	185
Asn Glu Cys Ala Thr Glu Asn Pro Cys Val Gln Thr Cys Val Asn Thr			
	190	195	200
Tyr Gly Ser Phe Ile Cys Arg Cys Asp Pro Gly Tyr Glu Leu Glu Glu			
	205	210	215
Asp Gly Val His Cys Ser Asp Met Asp Glu Cys Ser Phe Ser Glu Phe			
	220	225	230
Leu Cys Gln His Glu Cys Val Asn Gln Pro Gly Thr Tyr Phe Cys Ser			
	235	240	245
Cys Pro Pro Gly Tyr Ile Leu Leu Asp Asp Asn Arg Ser Cys Gln Asp			
250	255	260	265
Ile Asn Glu Cys Glu His Arg Asn His Thr Cys Asn Leu Gln Gln Thr			
	270	275	280
Cys Tyr Asn Leu Gln Gly Gly Phe Lys Cys Ile Asp Pro Ile Arg Cys			
	285	290	295
Glu Glu Pro Tyr Leu Arg Ile Ser Asp Asn Arg Cys Met Cys Pro Ala			
	300	305	310
Glu Asn Pro Gly Cys Arg Asp Gln Pro Phe Thr Ile Leu Tyr Arg Asp			
	315	320	325
Met Asp Val Val Ser Gly Arg Ser Val Pro Ala Asp Ile Phe Gln Met			
330	335	340	345
Gln Ala Thr Thr Arg Tyr Pro Gly Ala Tyr Tyr Ile Phe Gln Ile Lys			
	350	355	360
Ser Gly Asn Glu Gly Arg Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile			

365	370	375
Ser Ala Thr Leu Val Met Thr Arg Pro Ile Lys Gly Pro Arg Glu Ile		
380	385	390
Gln Leu Asp Leu Glu Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg		
395	400	405
Gly Ser Ser Val Ile Arg Leu Arg Ile Tyr Val Ser Gln Tyr Pro Phe		
410	415	420
		425

<210> 12

<211> 1344

<212> DNA

<213> Homo sapiens

<400> 12

atgccaggaa taaaaaggat actcactgtt accattcttg ctctctgtct tccaagccct 60
 gggaatgcac aggcacagtg cacgaatggc tttagacctgg atgccagtc aggacagtgt 120
 ttagatattg atgaatgccg aaccatcccc gaggcctgcc gaggagacat gatgtgtgtt 180
 aaccaaaatg gcgggtatth atgcattccc cggacaaacc ctgtgtatcg agggccctac 240
 tcgaaccctt actcgacccc ctactcaggt ccgtaccag cagctgcccc accactctca 300
 gctccaaact atcccacgat ctccaggcct cttatatgcc gctttggata ccagatggat 360
 gaaagcaacc aatgtgtgga tgtggacgag tgtgcaacag attcccacca gtgcaacccc 420
 acccagatct gcatcaatac tgaaggcggg tacacctgct cctgcaccga cggatattgg 480
 cttctggaag gccagtgcct agacattgat gaatgtcgct atggttactg ccagcagctc 540
 tgtgcgaatg ttcttgatc ctattcttgt acatgcaacc ctggttttac cctcaatgag 600
 gatggaaggt ctgccaaga tgtgaacgag tgtgccaccg agaaccctg cgtgcaaacc 660

tgcgtcaaca cctacggctc ttcatctgc cgctgtgacc caggatatga acttgaggaa 720
 gatggcggttc attgcagtga tatggacgag tgcagettct ctgagttcct ctgccaacat 780
 gagtgtgtga accagcccg cactacttc tgctctgcc ctccaggcta catcctgctg 840
 gatgacaacc gaagctgcca agacatcaac gaatgtgagc acaggaacca cacgtgcaac 900
 ctgcagcaga cgtgctacaa ttacaaagg ggcttcaaat gcatcgaccc catccgctgt 960
 gaggagcctt atctgaggat cagtgataac cgctgtatgt gtcttgetga gaacctgggc 1020
 tgcagagacc agccctttac catcttgtac cgggacatgg acgtggtgtc aggacgctcc 1080
 gttcccgctg acatcttcca aatgcaagcc acgacccgct accctggggc ctattacatt 1140
 ttccagatca aatctgggaa tgagggcaga gaattttaca tgcggcaaac gggccccatc 1200
 agtgcacccc tggatgatgac acgccccatc aaaggggccc gggaaatcca gctggacttg 1260
 gaaatgatca ctgtcaaacac tgcatacaac ttcagaggca gctccgtgat ccgactgcgg 1320
 atatatgtgt cgcagtaccc attc 1344

<210> 13

<211> 2328

<212> DNA

<213> Homo sapiens

<220>

<223> Clone human A55 derived from human brain

<220>

<221> CDS

<222> (169).. (1512)

0067437 332510

175	180	185	
gcc acc gag aac ccc tgc gtg caa acc tgc gtc aac acc tac ggc tct 849			
Ala Thr Glu Asn Pro Cys Val Gln Thr Cys Val Asn Thr Tyr Gly Ser			
190	195	200	
ttc atc tgc cgc tgt gac cca gga tat gaa ctt gag gaa gat ggc gtt 897			
Phe Ile Cys Arg Cys Asp Pro Gly Tyr Glu Leu Glu Glu Asp Gly Val			
205	210	215	220
cat tgc agt gat atg gac gag tgc agc ttc tct gag ttc ctc tgc caa 945			
His Cys Ser Asp Met Asp Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln			
	225	230	235
cat gag tgt gtg aac cag ccc ggc aca tac ttc tgc tcc tgc cct cca 993			
His Glu Cys Val Asn Gln Pro Gly Thr Tyr Phe Cys Ser Cys Pro Pro			
240	245	250	
ggc tac atc ctg ctg gat gac aac cga agc tgc caa gac atc aac gaa 1041			
Gly Tyr Ile Leu Leu Asp Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu			
255	260	265	
tgt gag cac agg aac cac acg tgc aac ctg cag cag acg tgc tac aat 1089			
Cys Glu His Arg Asn His Thr Cys Asn Leu Gln Gln Thr Cys Tyr Asn			
270	275	280	
tta caa ggg ggc ttc aaa tgc atc gac ccc atc cgc tgt gag gag cct 1137			
Leu Gln Gly Gly Phe Lys Cys Ile Asp Pro Ile Arg Cys Glu Glu Pro			
285	290	295	300
tat ctg agg atc agt gat aac cgc tgt atg tgt cct gct gag aac cct 1185			
Tyr Leu Arg Ile Ser Asp Asn Arg Cys Met Cys Pro Ala Glu Asn Pro			
	305	310	315
ggc tgc aga gac cag ccc ttt acc atc ttg tac cgg gac atg gac gtg 1233			

Gly Cys Arg Asp Gln Pro Phe Thr Ile Leu Tyr Arg Asp Met Asp Val
 320 325 330
 gtg tca gga cgc tcc gtt ccc gct gac atc ttc caa atg caa gcc acg 1281
 Val Ser Gly Arg Ser Val Pro Ala Asp Ile Phe Gln Met Gln Ala Thr
 335 340 345
 acc cgc tac cct ggg gcc tat tac att ttc cag atc aaa tct ggg aat 1329
 Thr Arg Tyr Pro Gly Ala Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn
 350 355 360
 gag ggc aga gaa ttt tac atg cgg caa acg ggc ccc atc agt gcc acc 1377
 Glu Gly Arg Glu Phe Tyr Met Arg Gln Thr Gly Pro Ile Ser Ala Thr
 365 370 375 380
 ctg gtg atg aca cgc ccc atc aaa ggg ccc cgg gaa atc cag ctg gac 1425
 Leu Val Met Thr Arg Pro Ile Lys Gly Pro Arg Glu Ile Gln Leu Asp
 385 390 395
 ttg gaa atg atc act gtc aac act gtc atc aac ttc aga ggc agc tcc 1473
 Leu Glu Met Ile Thr Val Asn Thr Val Ile Asn Phe Arg Gly Ser Ser
 400 405 410
 gtg atc cga ctg cgg ata tat gtg teg cag tac cca ttc tgagcctcgg 1522
 Val Ile Arg Leu Arg Ile Tyr Val Ser Gln Tyr Pro Phe
 415 420 425
 gctggagcct ccgacgtgc ctctcattgg caccaaggga caggagaaga gaggaataa 1582
 cagagagaat gagagcgaca cagacgttag gcatttcctg ctgaacgttt ccccgaagag 1642
 tcagccccga ctctctgact ctcacctgta ctattgcaga cctgtcaccc tgcaggactt 1702
 gccacccccca gtctctatga tacagttatc aaaaagtatt atcattgctc ccctgataga 1762
 agattgtttgg tgaattttca aggcttcag tttatttcca ctattttcaa agaaaataga 1822
 ttaggtttgc gggggtctga gtctatgttc aaagactgtg aacagcttgc tgteacttct 1882

tcacctcttc cactccttct ctcactgtgt tactgctttg caaagaccgg ggagctggcg 1942
 gggaaccctg ggagtagcta gtttgccttt tgcgtacaca gagaaggcta tgtaaacaaa 2002
 ccacagcagg atcgaagggt ttttagagaa tgtgtttcaa aaccatgcct ggtattttca 2062
 accataaaag aagtttcagt tgtccttaaa tttgtataac ggtttaattc tgtcttggtc 2122
 attttgagta tttttaaaaa atatgtcgta gaattccttc gaaaggcctt cagacacatg 2182
 ctatgttctg tcttcccaaa cccagtcctc tctccatttt agcccagtgt tttctttgag 2242
 gacccttaaa tcttgcttcc tttagaattt ttaccaatt ggattggaat gcagaggtct 2302
 ccaaactgat taaatatttg aagaga 2328

<210> 14

<211> 423

<212> PRT

<213> Homo sapiens

<400> 14

Gln Cys Thr Asn Gly Phe Asp Leu Asp Arg Gln Ser Gly Gln Cys Leu

1 5 10 15

Asp Ile Asp Glu Cys Arg Thr Ile Pro Glu Ala Cys Arg Gly Asp Met

20 25 30

Met Cys Val Asn Gln Asn Gly Gly Tyr Leu Cys Ile Pro Arg Thr Asn

35 40 45

Pro Val Tyr Arg Gly Pro Tyr Ser Asn Pro Tyr Ser Thr Pro Tyr Ser

50 55 60

Gly Pro Tyr Pro Ala Ala Ala Pro Pro Leu Ser Ala Pro Asn Tyr Pro

65 70 75 80

Thr Ile Ser Arg Pro Leu Ile Cys Arg Phe Gly Tyr Gln Met Asp Glu
 85 90 95
 Ser Asn Gln Cys Val Asp Val Asp Glu Cys Ala Thr Asp Ser His Gln
 100 105 110
 Cys Asn Pro Thr Gln Ile Cys Ile Asn Thr Glu Gly Gly Tyr Thr Cys
 115 120 125
 Ser Cys Thr Asp Gly Tyr Trp Leu Leu Glu Gly Gln Cys Leu Asp Ile
 130 135 140
 Asp Glu Cys Arg Tyr Gly Tyr Cys Gln Gln Leu Cys Ala Asn Val Pro
 145 150 155 160
 Gly Ser Tyr Ser Cys Thr Cys Asn Pro Gly Phe Thr Leu Asn Glu Asp
 165 170 175
 Gly Arg Ser Cys Gln Asp Val Asn Glu Cys Ala Thr Glu Asn Pro Cys
 180 185 190
 Val Gln Thr Cys Val Asn Thr Tyr Gly Ser Phe Ile Cys Arg Cys Asp
 195 200 205
 Pro Gly Tyr Glu Leu Glu Glu Asp Gly Val His Cys Ser Asp Met Asp
 210 215 220
 Glu Cys Ser Phe Ser Glu Phe Leu Cys Gln His Glu Cys Val Asn Gln
 225 230 235 240
 Pro Gly Thr Tyr Phe Cys Ser Cys Pro Pro Gly Tyr Ile Leu Leu Asp
 245 250 255
 Asp Asn Arg Ser Cys Gln Asp Ile Asn Glu Cys Glu His Arg Asn His
 260 265 270
 Thr Cys Asn Leu Gln Gln Thr Cys Tyr Asn Leu Gln Gly Gly Phe Lys
 275 280 285

Cys Ile Asp Pro Ile Arg Cys Glu Glu Pro Tyr Leu Arg Ile Ser Asp

290

295

300

Asn Arg Cys Met Cys Pro Ala Glu Asn Pro Gly Cys Arg Asp Gln Pro

305

310

315

320

Phe Thr Ile Leu Tyr Arg Asp Met Asp Val Val Ser Gly Arg Ser Val

325

330

335

Pro Ala Asp Ile Phe Gln Met Gln Ala Thr Thr Arg Tyr Pro Gly Ala

340

345

350

Tyr Tyr Ile Phe Gln Ile Lys Ser Gly Asn Glu Gly Arg Glu Phe Tyr

355

360

365

Met Arg Gln Thr Gly Pro Ile Ser Ala Thr Leu Val Met Thr Arg Pro

370

375

380

Ile Lys Gly Pro Arg Glu Ile Gln Leu Asp Leu Glu Met Ile Thr Val

385

390

395

400

Asn Thr Val Ile Asn Phe Arg Gly Ser Ser Val Ile Arg Leu Arg Ile

405

410

415

Tyr Val Ser Gln Tyr Pro Phe

420

<210> 15

<211> 1269

<212> DNA

<213> Homo sapiens

<400> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Primer

<400> 16

cgattgaatt ctagacctgc ctcgagnnnn nnnnn

35

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mA55-R1 Primer

<400> 17

cgtttgtgca ctgctgctgt gcattcc

27

SOLE/JOINT

1,2,3 & 12

DECLARATION AND POWER OF ATTORNEY

I/We as below named inventors, I/We hereby declare that our residence, mailing addresses and citizenship are as stated below next to my name: that verily believe I/We are the original, inventors (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

A NOVEL POLYPEPTIDE AND DNA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

Which application is:

☐ The attached application
(for original application)

☒ Application No. 09/674,379

filed October 30, 2000 as the U.S. national stage of
PCT/JP99/02284, filed April 28, 1999

(for declaration not accompanying application)

I/We have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware and which is material to the patentability of this application as defined in 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, §119(e) of any United States provisional application(s), or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International application having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed	
			Yes	No
Hei. 10-119731	Japanese	April 28, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I/We hereby claim the benefit under 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status
(33)		

I/We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603; George F. Lehnigk, Reg. No. 36,359; John T. Callahan, Reg. No. 32,607; Steven M. Gruskin, Reg. No. 36,818; Peter A. McKenna, Reg. No. 38,551 and Edward F. Kenchan, Reg. No. 28,962, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date <u>1-00</u>	First Inventor <u>Tasuku</u>	<u>HONJO</u>
Residence <u>Kyoto</u>	Japan <u>JPX</u>	Signature <u>[Signature]</u>
City	State/Country	

Mailing Address: 19-4, Ohsagi-cho, Iwakura, Sakyo-ku, Kyoto-shi, KYOTO 606-0001 JAPAN

Citizenship Japanese

Date 200 Second Inventor Kei TASHIRO
 Residence Kyoto Japan JPX Signature Kei Tashiro
 City State/Country First Name Middle Initial Last Name

Mailing Address: 93, Higashiobno-cho, Koyama, Kita-ku, Kyoto-shi, KYOTO 603-8162 JAPAN

Citizenship Japanese

Date 300 Third Inventor Tomoyuki NAKAMURA
 Residence San Diego, California U.S.A. CA Signature Tomoyuki Nakamura
 City State/Country First Name Middle Initial Last Name

Mailing Address: 7665, Palmira Dr., #5324, San Diego, CA

Citizenship Japanese

Date _____ Fourth Inventor X Kenneth JACOBS
 Residence Reading, MA U.S.A. Signature _____
 City State/Country First Name Middle Initial Last Name

Mailing Address: 151 Beaumont Avenue, Reading, MA 01867

Citizenship U.S.

Date _____ Fifth Inventor X John M. McCoy
 Residence Reading, MA U.S.A. Signature _____
 City State/Country First Name Middle Initial Last Name

Mailing Address: 56 Howard Street, Reading, MA 01867

Citizenship U.K.

Date _____ Sixth Inventor X Lisa A. Collins-Racie
 Residence Acton, MA U.S.A. Signature _____
 City State/Country First Name Middle Initial Last Name

Mailing Address: 124 School Street, Acton, MA 01720

Citizenship U.S.

Date _____ Seventh Inventor Edward R. LaVallie
 Residence Harvard, MA U.S.A. Signature
 City State/Country First Name Middle Initial Last Name

Mailing Address: 113 Ann Lee Road, Harvard, MA 01452

Citizenship U.S.

Date _____ Eighth Inventor Maurice Treacy
 Residence Dun Laoghaire, IRELAND Signature
 City County of Dublin State/Country First Name Middle Initial Last Name

Mailing Address: 38 Clarinda Park East, Dun Laoghaire, County Dublin, IRELAND

Citizenship IRELAND

Date _____ Ninth Inventor Cheryl Evans
 Residence Germantown, MD U.S.A. Signature
 City State/Country First Name Middle Initial Last Name

Mailing Address: 19326 Golden Meadow Drive, Germantown, MD 20876

Citizenship United Kingdom

Date _____ Tenth Inventor Michael J. Agostino
 Residence Andover, MA U.S.A. Signature
 City State/Country First Name Middle Initial Last Name

Mailing Address: 26 Wolcott Avenue, Andover, MA 01810

Citizenship U.S.

Date _____ Eleventh Inventor Zhijian Lu
 Residence Bedford, MA U.S.A. Signature
 City State/Country First Name Middle Initial Last Name

Mailing Address: 120 Old Burlington Road, Bedford, MA 01730

Citizenship People's Rep. Of China

SOLE/JOINT

4,6,7,10,11

DECLARATION AND POWER OF ATTORNEY

I/We as below named inventors, I/We hereby declare that our residence, mailing addresses and citizenship are as stated below next to my name: that verily believe I/We are the original, inventors (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

A NOVEL POLYPEPTIDE, A cDNA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

Which application is:

☐ The attached application
(for original application)

☒ Application No. 09/674,379
filed October 30, 2000 as the U.S. national stage of
PCT/JP99/02284, filed April 28, 1999

(for declaration not accompanying application)

I/We have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware and which is material to the patentability of this application as defined in 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, §119(e) of any United States provisional application(s), or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International application having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed	
			Yes	No
Hei. 10-119731	Japanese	April 28, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I/We hereby claim the benefit under 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status
-----------------	-------------	--------

I/We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603; George F. Lehnigk, Reg. No. 36,359; John T. Callahan, Reg. No. 32,607; Steven M. Gruskin, Reg. No. 36,818; Peter A. McKenna, Reg. No. 38,551 and Edward F. Kenenhan, Reg. No. 28,962, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date	First Inventor	Tasuku	HONJO
Residence	Kyoto	Japan	Signature
	City	State/Country	

Mailing Address: 19-4, Ohsagi-cho, Iwakura, Sakyo-ku, Kyoto-shi, KYOTO 606-0001 JAPAN

Citizenship Japanese

Date _____ Second Inventor Kei TASHIRO
 First Name Middle Initial Last Name
 Residence Kyoto Japan Signature Kei Tashiro
 City State/Country

Mailing Address: 93, Higashiohno-cho, Koyama, Kita-ku, Kyoto-shi, KYOTO 603-8162 JAPAN

Citizenship Japanese

Date _____ Third Inventor Tomoyuki NAKAMURA
 First Name Middle Initial Last Name
 Residence San Diego, California U.S.A. Signature Tomoyuki Nakamura
 City State/Country

Mailing Address: 7665, Palmira Dr., #5324, San Diego, CA

Citizenship Japanese

Date 4-08 _____ Fourth Inventor Kenneth JACOBS
 First Name Middle Initial Last Name
 Residence Reading, MA U.S.A. Signature Kenneth Jacobs
 City State/Country

Mailing Address: 151 Beaumont Avenue, Reading, MA 01867 MA

Citizenship U.S.

Date _____ Fifth Inventor John M. McCoy
 First Name Middle Initial Last Name
 Residence Reading, MA U.S.A. Signature _____
 City State/Country


Mailing Address: 56 Howard Street, Reading, MA 01867

Citizenship U.K.

Date 11/27/01 _____ Sixth Inventor Lisa A. Collins-Racie
 First Name Middle Initial Last Name
 Residence Acton, MA U.S.A. Signature Lisa A. Collins-Racie
 City State/Country

Mailing Address: 124 School Street, Acton, MA 01720 MA

Citizenship U.S.

Date _____ Twelfth Inventor David Merberg
 _____ First Name Middle Initial Last Name
 Residence Acton, MA U.S.A. Signature 
 _____ City State/Country
 Mailing Address: 2 Orchard Drive, Acton, MA 01720

 Citizenship U.S.

DECLARATION AND POWER OF ATTORNEY

I/We as below named inventors, I/We hereby declare that our residence, mailing addresses and citizenship are as stated below next to my name: that verily believe I/We are the original; inventors (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

A NOVEL POLYPEPTIDE DNA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

Which application is:

☐ The attached application
(for original application)

☒ Application No. 09/674,379

filed October 30, 2000 as the U.S. national stage of
PCT/JP99/02284, filed April 28, 1999

(for declaration not accompanying application)

I/We have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware and which is material to the patentability of this application as defined in 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, §119(e) of any United States provisional application(s), or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International application having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed	
			Yes	No
Hei. 10-119731	Japanese	April 28, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I/We hereby claim the benefit under 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status

I/We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603; George F. Lehnigk, Reg. No. 36,359; John T. Callahan, Reg. No. 32,607; Steven M. Gruskin, Reg. No. 36,818; Peter A. McKenna, Reg. No. 38,551 and Edward F. Kenenhan, Reg. No. 28,962, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date	First Inventor	Tasuku	HONJO
		First Name	Middle Initial Last Name

Residence	Kyoto	Japan	Signature
	City	State/Country	

Mailing Address: 19-4, Ohsagi-cho, Iwakura, Sakyo-ku, Kyoto-shi, KYOTO 606-0001 JAPAN

Citizenship Japanese

Date _____ Second Inventor Kei TASHIRO
 First Name Middle Initial Last Name
 Residence Kyoto Japan Signature Kei Tashiro
 City State/Country

Mailing Address: 93, Higashiohno-cho, Koyama, Kita-ku, Kyoto-shi, KYOTO 603-8162 JAPAN

Citizenship Japanese

Date _____ Third Inventor Tomoyuki NAKAMURA
 First Name Middle Initial Last Name
 Residence San Diego, California U.S.A. Signature Tom Nahn
 City State/Country

Mailing Address: 7665, Palmira Dr., #5324, San Diego, CA

Citizenship Japanese

Date _____ Fourth Inventor Kenneth JACOBS
 First Name Middle Initial Last Name
 Residence Reading, MA U.S.A. Signature _____
 City State/Country

Mailing Address: 151 Beaumont Avenue, Reading, MA 01867

Citizenship U.S.

500 11/22/01 Date Fifth Inventor John M. McCoy
 First Name Middle Initial Last Name
 Residence Reading, MA U.S.A. Signature John M. McCoy
 City State/Country

Mailing Address: 56 Howard Street, Reading, MA 01867 MA

Citizenship U.K.

Date _____ Sixth Inventor Lisa A. Collins-Racie
 First Name Middle Initial Last Name
 Residence Acton, MA U.S.A. Signature _____
 City State/Country

Mailing Address: 124 School Street, Acton, MA 01720

Citizenship U.S.

Date _____ Seventh Inventor Edward R. LaVallie
First Name Middle Initial Last Name
Residence Harvard, MA U.S.A. Signature _____
City State/Country

Mailing Address: 113 Ann Lee Road, Harvard, MA 01452

Citizenship U.S.

Date _____ Eighth Inventor Maurice Treacy
First Name Middle Initial Last Name
Residence Dun Laoghaire, IRELAND Signature _____
County of Dublin State/Country
City

Mailing Address: 38 Clarinda Park East, Dun Laoghaire, County Dublin, IRELAND

Citizenship IRELAND

Date _____ Ninth Inventor Cheryl Evans
First Name Middle Initial Last Name
Residence Germantown, MD U.S.A. Signature _____
City State/Country

Mailing Address: 19326 Golden Meadow Drive, Germantown, MD 20876

Citizenship United Kingdom

Date _____ Tenth Inventor Michael J. Agostino
First Name Middle Initial Last Name
Residence Andover, MA U.S.A. Signature _____
City State/Country

Mailing Address: 26 Wolcott Avenue, Andover, MA 01810

Citizenship U.S.

Date _____ Eleventh Inventor Zhijian Lu
First Name Middle Initial Last Name
Residence Bedford, MA U.S.A. Signature _____
City State/Country

Mailing Address: 120 Old Burlington Road, Bedford, MA 01730

Citizenship People's Rep. Of China

DECLARATION AND POWER OF ATTORNEY

I/We as below named inventors, I/We hereby declare that our residence, mailing addresses and citizenship are as stated below next to my name: that verily believe I/We are the original, inventors (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

A NOVEL POLYPEPTIDE A-DNA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

Which application is:

☐ The attached application
(for original application)

☒ Application No. 09/674,379
filed October 30, 2000 as the U.S. national stage of
PCT/JP99/02284, filed April 28, 1999

(for declaration not accompanying application)

I/We have reviewed and understand the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware and which is material to the patentability of this application as defined in 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, §119(e) of any United States provisional application(s), or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International application having a filing date before that of the application on which priority is claimed:

Application Number	Country	Filing Date	Priority Claimed	
			Yes	No
Hei. 10-119731	Japanese	April 28, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I/We hereby claim the benefit under 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status
-----------------	-------------	--------

I/We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603; George F. Lehnigk, Reg. No. 36,359; John T. Callahan, Reg. No. 32,607; Steven M. Gruskin, Reg. No. 36,818; Peter A. McKenna, Reg. No. 38,551 and Edward F. Kenehan, Reg. No. 28,962, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date	First Inventor	Tasuku	HONJO
		First Name	Middle Initial Last Name
Residence	Kyoto	Japan	Signature
	City	State/Country	

Mailing Address: 19-4, Ohsagi-cho, Iwakura, Sakyo-ku, Kyoto-shi, KYOTO 606-0001 JAPAN

Citizenship Japanese

Date _____ Second Inventor Kei TASHIRO
First Name Middle Initial Last Name
Residence Kyoto Japan Signature Kei Tashiro
City State/Country

Mailing Address: 93, Higashiohno-cho, Koyama, Kita-ku, Kyoto-shi, KYOTO 603-8162 JAPAN

Citizenship Japanese

Date _____ Third Inventor Tomoyuki NAKAMURA
First Name Middle Initial Last Name
Residence San Diego, California U.S.A. Signature Tom Nahn
City State/Country

Mailing Address: 7665, Palmira Dr., #5324, San Diego, CA

Citizenship Japanese

Date _____ Fourth Inventor Kenneth JACOBS
First Name Middle Initial Last Name
Residence Reading, MA U.S.A. Signature _____
City State/Country

Mailing Address: 151 Beaumont Avenue, Reading, MA 01867

Citizenship U.S.

Date _____ Fifth Inventor John M. McCoy
First Name Middle Initial Last Name
Residence Reading, MA U.S.A. Signature _____
City State/Country

Mailing Address: 56 Howard Street, Reading, MA 01867

Citizenship U.K.

Date _____ Sixth Inventor Lisa A. Collins-Racie
First Name Middle Initial Last Name
Residence Acton, MA U.S.A. Signature _____
City State/Country

Mailing Address: 124 School Street, Acton, MA 01720

Citizenship U.S.

Date _____ Seventh Inventor Edward R. LaVallie
 First Name Middle Initial Last Name
 Residence Harvard, MA U.S.A. Signature _____
 City State/Country

Mailing Address: 113 Ann Lee Road, Harvard, MA 01452

Citizenship U.S.

Date December 03, 2001 Eighth Inventor Maurice Treacy
 First Name Middle Initial Last Name
 Residence Dun Laoghaire, IRELAND IRE Signature _____
 City State/Country

Mailing Address: 38 Clarinda Park East, Dun Laoghaire, County Dublin, IRELAND

Citizenship IRELAND

Date _____ Ninth Inventor Cheryl Evans
 First Name Middle Initial Last Name
 Residence Germantown, MD U.S.A. Signature _____
 City State/Country

Mailing Address: 19326 Golden Meadow Drive, Germantown, MD 20876

Citizenship United Kingdom

Date _____ Tenth Inventor Michael J. Agostino
 First Name Middle Initial Last Name
 Residence Andover, MA U.S.A. Signature _____
 City State/Country

Mailing Address: 26 Wolcott Avenue, Andover, MA 01810

Citizenship U.S.

Date _____ Eleventh Inventor Zhijian Lu
 First Name Middle Initial Last Name
 Residence Bedford, MA U.S.A. Signature _____
 City State/Country

Mailing Address: 120 Old Burlington Road, Bedford, MA 01730

Citizenship People's Rep. Of China

Date _____ Twelfth Inventor David Merberg
 Residence Acton, MA U.S.A. Signature [Signature]
 City State/Country First Name Middle Initial Last Name
 Mailing Address: 2 Orchard Drive, Acton, MA 01720

 Citizenship U.S.

SOLE/JOINT

DECLARATION AND POWER OF ATTORNEY

I/We as below named inventors, I/We hereby declare that our residence, mailing addresses and citizenship are as stated below next to my name: that verily believe I/We are the original, inventors (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought in the application entitled:

A NOVEL POLYPEPTIDE, A GENA ENCODING THE POLYPEPTIDE AND UTILIZATION THEREOF

Which application is:

☐ The attached application
(for original application)

☒ Application No. 09/674,379
filed October 30, 2000 as the U.S. national stage of
PCT/JP99/02284, filed April 28, 1999

(for declaration not accompanying application)

I/We have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that I acknowledge my duty to disclose information of which I am aware and which is material to the patentability of this application as defined in 37 C.F.R. 1.56, that I hereby claim priority benefits under Title 35, United States Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, §119(e) of any United States provisional application(s), or §365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT International application having a filing date before that of the application on which priority is claimed:


Application Number	Country	Filing Date	Priority Claimed	
			Yes	No
Hei. 10-119731	Japanese	April 28, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I/We hereby claim the benefit under 35 United States Code §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date	Status
-----------------	-------------	--------

I/We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603; George F. Lehnigk, Reg. No. 36,359; John T. Callahan, Reg. No. 32,607; Steven M. Gruskin, Reg. No. 36,818; Peter A. McKenna, Reg. No. 38,551 and Edward F. Kenenhan, Reg. No. 28,962, my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

I/We hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date	First Inventor	Tasuku	HONJO
		First Name	Middle Initial Last Name
Residence	Kyoto Japan	Signature	
	City State/Country		

Mailing Address: 19-4, Ohsagi-cho, Iwakura, Sakyo-ku, Kyoto-shi, KYOTO 606-0001 JAPAN

Citizenship Japanese

Date _____ Second Inventor Kei TASHIRO
First Name Middle Initial Last Name
Residence Kyoto Japan Signature Kei Tashiro
City State/Country

Mailing Address: 93, Higashiohno-cho, Koyama, Kita-ku, Kyoto-shi, KYOTO 603-8162 JAPAN

Citizenship Japanese

Date _____ Third Inventor Tomoyuki NAKAMURA
First Name Middle Initial Last Name
Residence San Diego, California U.S.A. Signature Tom Nahn
City State/Country

Mailing Address: 7665, Palmira Dr., #5324, San Diego, CA

Citizenship Japanese

Date _____ Fourth Inventor Kenneth JACOBS
First Name Middle Initial Last Name
Residence Reading, MA U.S.A. Signature _____
City State/Country

Mailing Address: 151 Beaumont Avenue, Reading, MA 01867

Citizenship U.S.

Date _____ Fifth Inventor John M. McCoy
First Name Middle Initial Last Name
Residence Reading, MA U.S.A. Signature _____
City State/Country

Mailing Address: 56 Howard Street, Reading, MA 01867

Citizenship U.K.

Date _____ Sixth Inventor Lisa A. Collins-Racie
First Name Middle Initial Last Name
Residence Acton, MA U.S.A. Signature _____
City State/Country

Mailing Address: 124 School Street, Acton, MA 01720

Citizenship U.S.

Date _____ Seventh Inventor Edward R. LaVallie
 Residence Harvard, MA U.S.A. First Name Middle Initial Last Name
 City State/Country Signature

Mailing Address: 113 Ann Lee Road, Harvard, MA 01452

Citizenship U.S.

Date _____ Eighth Inventor Maurice Treacy
 Residence Dun Laoghaire, IRELAND First Name Middle Initial Last Name
 County of Dublin City State/Country Signature

Mailing Address: 38 Clarinda Park East, Dun Laoghaire, County Dublin, IRELAND

Citizenship IRELAND

9-000 Date 11/29/01 Ninth Inventor Cheryl Evans
 Residence Germantown, MD U.S.A. First Name Middle Initial Last Name
 City State/Country Signature

Mailing Address: 19326 Golden Meadow Drive, Germantown, MD 20876

Citizenship United Kingdom

Date _____ Tenth Inventor Michael J. Agostino
 Residence Andover, MA U.S.A. First Name Middle Initial Last Name
 City State/Country Signature

Mailing Address: 26 Wolcott Avenue, Andover, MA 01810

Citizenship U.S.

Date _____ Eleventh Inventor Zhijian Lu
 Residence Bedford, MA U.S.A. First Name Middle Initial Last Name
 City State/Country Signature

Mailing Address: 120 Old Burlington Road, Bedford, MA 01730

Citizenship People's Rep. Of China

09674379 012502

Date _____ Twelfth Inventor David Merberg
First Name Middle Initial Last Name
Residence Acton, MA U.S.A. Signature [Signature]
City State/Country
Mailing Address: 2 Orchard Drive, Acton, MA 01720
Citizenship U.S.

Date 7-00 Seventh Inventor Edward R. LaVallie
 Residence Harvard, MA U.S.A. Signature Edward R. LaVallie
 City State/Country
 Mailing Address: 113 Ann Lee Road; Harvard, MA 01457
 Citizenship U.S.

Date _____ Eighth Inventor Maurice Treacy
 Residence Dun Laoghaire, IRELAND Signature _____
 City County of Dublin State/Country
 Mailing Address: 38 Clarinda Park East, Dun Laoghaire, County Dublin, IRELAND
 Citizenship IRELAND

Date _____ Ninth Inventor Cheryl Evans
 Residence Germantown, MD U.S.A. Signature _____
 City State/Country
 Mailing Address: 19326 Golden Meadow Drive, Germantown, MD 20876
 Citizenship United Kingdom

Date 10-00 Tenth Inventor Michael J. Agostino
 Residence Andover, MA MA U.S.A. Signature Michael J. Agostino
 City State/Country
 Mailing Address: 26 Wolcott Avenue, Andover, MA 01810
 Citizenship U.S.

Date 11-00 11/27/2001 Eleventh Inventor Zhijian Lu
 Residence Bedford, MA MA U.S.A. Signature Zhijian Lu
 City State/Country
 Mailing Address: 120 Old Burlington Road, Bedford, MA 01730
 Citizenship People's Rep. Of China

09674379 012502

Date 12-00 Dec 11 2001 Twelfth Inventor David Merberg
Residence Acton, MA MA U.S.A. First Name Middle Initial Last Name
City State/Country Signature David Merberg

Mailing Address: 2 Orchard Drive, Acton, MA 01720

Citizenship U.S.

